Compositions comprising polypeptides having xylanase activity and polypeptides having arabinofuranosidase activity

Abstract

Compositions comprising a polypeptide having xylanase activity and a polypeptide having arabinofuranosidase activity are disclosed for use, for example, in animal feed. Polypeptides having arabinofuranosidase activity, polypeptides having xylanase activity, and polynucleotides encoding the polypeptides are disclosed. Nucleic acid constructs, vectors, and host cells comprising the polynucleotides are disclosed as well as methods of producing and using the polypeptides.

Description

[0001] This application is a divisional application of a Chinese invention patent application filed on December 18, 2015, with application number 202210237899.3, and invention name “A composition comprising a polypeptide having xylanase activity and a polypeptide having arabinofuranosidase activity”.

[0002] Reference to a sequence listing

[0003] This application contains a Sequence Listing in computer readable form, which is incorporated herein by reference. Background of the Invention Field of the Invention

[0005] The present invention relates to a composition comprising a polypeptide having xylanase activity and a polypeptide having arabinofuranosidase activity for use in, for example, animal feed. The present invention further relates to polypeptides having arabinofuranosidase activity, polypeptides having xylanase activity, and polynucleotides encoding these polypeptides. The present invention also relates to nucleic acid constructs, vectors, and host cells comprising these polynucleotides, as well as methods of producing and using these polypeptides.

[0006] Related technical description

[0007] Xylans are hemicelluloses found in all terrestrial plants (Popper and Tuohy, Plant Physiol., 2010, 153: 373-383). They are especially abundant in secondary cell walls and wood cells. In grasses with type II cell walls, glucuronic acid arabinoxylans are the main hemicelluloses and exist as soluble or insoluble dietary fibers in many grass-based foods and feed products.

[0008] Plant xylan has a β-1,4-linked xylanose main chain that can be substituted by arabinose, 4-O-methyl-glucuronic acid, glucuronic acid and acetic acid at the O2 or O3 position in a species- and tissue-specific manner. The starch-rich seeds of Panicoideae and economically important species (e.g., corn and sorghum) have a special type of highly substituted xylan in their cell walls. Compared with wheat flour in which more than 60% of the xylose units in the arabinoxylan main chain are unsubstituted, the corresponding percentage of unsubstituted main chain xylose is 20%-30% in corn kernel xylan, and 35%-40% in sorghum (Huismann et al., Carbohydrate Polymers, 2000, 42: 269-279). In addition, in corn and sorghum, these xylan side chains can be replaced longer than the single arabinose or glucuronic acid of typical other xylans. This additional side chain complexity is usually due to the L- and D-galactose and D-xylose that are bound to the side chain arabinose or (4-O-methyl)-glucuronic acid. About one eleventh of the arabinose in corn kernel xylan is also esterified with ferulic acid, and about one fifth of the xylose is acetylated (Agger et al., Journal of Agriculture and Food Chemistry (J.Agric.Food Chem), 2010, 58:6141-6148). All these factors combined make the highly substituted xylan in corn and sorghum resist the degradation caused by traditional xylanase.

[0009] Based on sequence similarity, the known enzymes responsible for the hydrolysis of carbohydrate-based polymers are classified into enzyme families (www.cazy.org). The enzymes within the family share some features, such as 3D folding, and they usually have the same reaction mechanism in common. Some GH families have narrow or single substrate specificity, while other families have broad substrate specificity. These enzymes that mainly have endo-xylanase activity have been described in glycoside hydrolase families (GH) 5, 8, 10, 11 and 30 before. These enzymes that mainly have alpha-arabinofuranosidase activity have been described in glycoside hydrolase families (GH) 3, 43, 51, 54 and 62 before.

[0010] Commercially available GH10 and GH11 xylanases are usually used to decompose the xylose backbone of arabinoxylan. In animal feed, this results in the degradation of cereal cell walls, with subsequent improvement in the release of nutrients (starch and protein) encapsulated in the cell. The degradation of xylan also results in the formation of xylose oligomers, which can be used for hindgut fermentation, and therefore help animals obtain more digestible energy. However, this xylanase is sensitive to side chain steric hindrance, and although they effectively degrade the arabinoxylan from wheat, they are not very effective to the arabinoxylan found in the seeds of Panicum subfamily species (e.g. corn or sorghum).

[0011] WO 2009 / 108941 proposes the use of more than 500 different polypeptide sequences with many following activities in numerous different applications, such as cellulase, ligninase, beta-glucosidase, hemicellulase, xylanase, alpha-amylase, amyloglucosidase, pectate lyase, cutinase, lipase, pectinase or maltogenic alpha-amylase activity. WO 2009 / 018537 proposes the use of multiple glycosyl hydrolases and ferulic acid esterases with different activities for converting lignocellulosic biomass into fermentable sugars. WO 2013 / 182669 discloses multiple glycosyl hydrolases with different activities from Myriococcum thermophilum strain CBS 389.93 and their use in biomass treatment. WO 2009 / 108941 proposes the use of yeast strains secreting multiple enzymes with different activities for biomass hydrolysis.

[0012] Corn is used in animal feed worldwide and therefore there is a need to find new solutions that can break down the highly branched xylan backbone in the cell wall in order to release more starch and other nutrients trapped in the cell wall. SUMMARY OF THE INVENTION

[0014] The present invention relates to a composition comprising one or more GH10 or GH11 polypeptides having xylanase activity and one or more GH62 polypeptides having arabinofuranosidase activity, wherein:

[0015] (a) GH62 polypeptide comprises the motif [H / Y][L / M]F[F / S][A / C / H / S / T / V][A / D / G / N / R]D[D / E / N]G (SEQ ID NO: 1);

[0016] (b) the GH10 or GH11 polypeptide together with the GH62 polypeptide solubilizes at least 2.0% xylose from defatted destarched maize (DFDSM); and

[0017] (c) the GH10 or GH11 polypeptide together with the GH62 polypeptide solubilizes at least 2 times more xylose from DFDSM than the GH10 or GH11 polypeptide can solubilize in the absence of the GH62 polypeptide;

[0018] Wherein (b) and (c) are carried out under the following reaction conditions:

[0019] i) 25 mg GH10 or GH11 polypeptide / kg DFDSM,

[0020] ii) 12.5 mg GH62 polypeptide / kg DFDSM, and

[0021] iii) Incubate at 40°C, pH 5 for 4 hours.

[0022] The present application further relates to isolated polypeptides having arabinofuranosidase activity, isolated polypeptides having xylanase activity, compositions comprising polypeptides having arabinofuranosidase activity and / or xylanase activity, animal feeds and animal feed additives comprising one or more polypeptides of the present invention, methods for improving animal performance (comprising administering to an animal a composition of the present invention); methods for improving the nutritional value of an animal feed (comprising administering to an animal a composition of the present invention); methods for solubilizing xylose from a plant-based material (comprising treating a plant-based material from the subfamily Panicum with a composition of the present invention); methods for releasing starch from a plant-based material (comprising treating a plant-based material from the subfamily Panicum with a composition of the present invention); methods for improving the nutritional value of an animal feed; The present invention relates to a method for improving the nutritional value of an animal feed (comprising adding the composition of the present invention to a feed); a method for preparing an animal feed (comprising mixing the composition of the present invention with a plant-based material from the subfamily Panicum spp.); the use of the composition of the present invention in the following items: in animal feed, in an animal feed additive, in the preparation of a composition for use in animal feed, for improving the nutritional value of an animal feed, for improving the digestibility of an animal feed, for improving one or more performance parameters in an animal, for releasing xylose from a plant-based material of the subfamily Panicum spp., and / or for releasing starch from a plant-based material of the subfamily Panicum spp.; polynucleotides encoding the polypeptides of the present invention; nucleic acid constructs comprising these polynucleotides; expression vectors; recombinant host cells; and methods for producing these polypeptides.

[0023] This application also specifically involves the following projects:

[0024] 1. A composition comprising one or more GH10 or GH11 polypeptides having xylanase activity and one or more GH62 polypeptides having arabinofuranosidase activity, wherein:

[0025] (a) GH62 polypeptide comprises the motif [H / Y][L / M]F[F / S][A / C / H / S / T / V][A / D / G / N / R]D[D / E / N]G (SEQ ID NO: 1);

[0026] (b) the GH10 or GH11 polypeptide together with the GH62 polypeptide solubilizes at least 2.0% xylose from defatted destarched maize (DFDSM); and

[0027] (c) the GH10 or GH11 polypeptide together with the GH62 polypeptide solubilizes at least 2 times more xylose from DFDSM than the GH10 or GH11 polypeptide can solubilize in the absence of the GH62 polypeptide;

[0028] Wherein (b) and (c) are carried out under the following reaction conditions:

[0029] i) 25 mg GH10 or GH11 polypeptide / kg DFDSM,

[0030] ii) 12.5 mg GH62 polypeptide / kg DFDSM, and

[0031] iii) Incubate at 40°C, pH 5 for 4 hours.

[0032] 2. A composition as described in item 1, wherein the GH62 polypeptide comprises one or more motifs selected from the following list, the list consisting of the following items: [H / Y]LF[F / S][A / S / V][A / D / G]DNG (SEQ ID NO: 2), YLFF[A / V][A / G]DNG (SEQ ID NO: 3), YLFFAGDNG (SEQ ID NO: 4),

[0033] [H / Y] LFSSDDNG (SEQ ID NO: 5), and YLFSSDDNG (SEQ ID NO: 6).

[0034] 3. The composition of any one of items 1 to 2, wherein the GH62 polypeptide having arabinofuranosidase activity is selected from the group consisting of:

[0035] (a) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 9;

[0036] (b) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 12;

[0037] (c) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 15;

[0038] (d) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 18;

[0039] (e) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 21;

[0040] (f) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 24;

[0041] (g) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 27;

[0042] (h) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 30;

[0043] (i) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 36;

[0044] (j) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO:42;

[0045] (k) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 48;

[0046] (l) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO:54;

[0047] (m) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 60;

[0048] (n) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 66;

[0049] (o) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 105;

[0050] (p) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 108;

[0051] (q) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 114;

[0052] (r) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 120;

[0053] (s) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 123;

[0054] (t) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 126;

[0055] (u) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 132;

[0056] (v) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 138;

[0057] (w) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 141;

[0058] (x) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 147;

[0059] (y) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 150;

[0060] (z) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 156;

[0061] (aa) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 159;

[0062] (ab) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 162;

[0063] (ac) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 165;

[0064] (ad) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 168;

[0065] (ae) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 171;

[0066] (af) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 174;

[0067] (ag) a variant of a polypeptide selected from the group consisting of SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:36, SEQ ID NO:42, SEQ ID NO:48, SEQ ID NO:54, SEQ ID NO:60, SEQ ID NO:66 SEQ ID NO:105, SEQ ID NO:108, SEQ ID NO:114, SEQ ID NO:120, SEQ ID NO:123, SEQ ID NO:126, SEQ ID NO:132, SEQ ID NO:138, SEQ ID NO:141, SEQ ID NO:147, SEQ ID NO:150, SEQ ID NO:156, SEQ ID NO:159, SEQ ID NO:162, SEQ ID NO:165, SEQ ID NO:168, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172 NO: 171 and SEQ ID NO: 174, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions in 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof;

[0068] (ah) a polypeptide comprising the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w), (x), (y), (z), (aa), (ab), (ac), (ad), (ae), (af) or (ag) and an N-terminal and / or C-terminal His-tag and / or HQ-tag; and

[0069] (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w), (x), (y), (z), (aa), (ab), (ac), (ad), (ae), (af), (ag) or (ah), which fragment has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide.

[0070] 4. The composition according to item 3, wherein the GH62 polypeptide having arabinofuranosidase activity comprises or consists of amino acids 1 to 302 of SEQ ID NO: 9, amino acids 1 to 303 of SEQ ID NO: 12, amino acids 1 to 382 of SEQ ID NO: 15, amino acids 1 to 378 of SEQ ID NO: 18, amino acids 1 to 311 of SEQ ID NO: 21, amino acids 1 to 302 of SEQ ID NO: 24, amino acids 1 to 309 of SEQ ID NO: 27, amino acids 1 to 438 of SEQ ID NO: 30, amino acids 1 to 446 of SEQ ID NO: 33, amino acids 1 to 438 of SEQ ID NO: 36, amino acids 1 to 446 of SEQ ID NO: 39, amino acids 1 to 318 of SEQ ID NO: 42, amino acids 1 to 326 of SEQ ID NO: 45, amino acids 1 to 302 of SEQ ID NO: 48, amino acids 1 to 311 of SEQ ID NO: 51, amino acids 1 to 309 of SEQ ID NO: 52 1 to 364 of SEQ ID NO:54, amino acids 1 to 373 of SEQ ID NO:57, amino acids 1 to 436 of SEQ ID NO:60, amino acids 1 to 444 of SEQ ID NO:63, amino acids 1 to 302 of SEQ ID NO:66, amino acids 1 to 311 of SEQ ID NO:69, amino acids 1 to 302 of SEQ ID NO:105, amino acids 1 to 464 of SEQ ID NO:108, amino acids 1 to 472 of SEQ ID NO:111, amino acids 1 to 364 of SEQ ID NO:114, amino acids 1 to 372 of SEQ ID NO:117, amino acids 1 to 357 of SEQ ID NO:120, amino acids 1 to 302 of SEQ ID NO:123, amino acids 1 to 453 of SEQ ID NO:126, amino acids 1 to 461 of SEQ ID NO:129, amino acids 1 to 377 of SEQ ID NO:132, 1 to 316 of SEQ ID NO: 159, amino acids 1 to 303 of SEQ ID NO: 162, amino acids 1 to 361 of SEQ ID NO: 165,Amino acids 1 to 373 of SEQ ID NO: 168, amino acids 1 to 302 of SEQ ID NO: 171, or amino acids 1 to 364 of SEQ ID NO: 174.

[0071] 5. The composition of any one of items 1 to 4, wherein the GH10 or GH11 polypeptide having xylanase activity is selected from the group consisting of:

[0072] (a) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 70;

[0073] (b) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 71;

[0074] (c) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 72;

[0075] (d) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 73;

[0076] (e) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 74;

[0077] (f) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 75;

[0078] (g) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 78;

[0079] (h) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 81;

[0080] (i) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 84;

[0081] (j) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 88;

[0082] (k) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 89;

[0083] (l) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO:95;

[0084] (m) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO:96;

[0085] (n) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO:99;

[0086] (o) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 102;

[0087] (p) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 177;

[0088] (q) a variant of a polypeptide selected from the group consisting of SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:78, SEQ ID NO:81, SEQ ID NO:84, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:99, SEQ ID NO:102, and SEQ ID NO:177, wherein the variant has xylanase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions in 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions, or any combination thereof;

[0089] (r) a polypeptide comprising the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p) or (q) and an N-terminal and / or C-terminal His-tag and / or HQ-tag; and

[0090] (s) (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q) or (r) The fragment has xylanase activity and has at least 90% of the length of the mature polypeptide.

[0091] 6. The composition according to item 5, wherein the GH10 or GH11 polypeptide comprises or consists of amino acids 1 to 384 of SEQ ID NO: 70, amino acids 1 to 288 of SEQ ID NO: 71, amino acids 1 to 308 of SEQ ID NO: 72, amino acids 1 to 195 of SEQ ID NO: 73, amino acids 1 to 203 of SEQ ID NO: 74, amino acids 1 to 182 of SEQ ID NO: 75, amino acids 1 to 183 of SEQ ID NO: 78, amino acids 1 to 181 of SEQ ID NO: 81, amino acids 1 to 299 of SEQ ID NO: 84, amino acids 1 to 307 of SEQ ID NO: 87, amino acids 1 to 188 of SEQ ID NO: 88, amino acids 1 to 189 of SEQ ID NO: 89, amino acids 1 to 328 of SEQ ID NO: 95, amino acids 1 to 208 of SEQ ID NO: 96, amino acids 1 to 203 of SEQ ID NO: 99, Amino acids 1 to 337 of SEQ ID NO:102, or amino acids 1 to 323 of SEQ ID NO:177.

[0092] 7. An isolated polypeptide having arabinofuranosidase activity, the polypeptide being selected from the group consisting of:

[0093] (a) a polypeptide having at least 85% sequence identity to the polypeptide of SEQ ID NO: 12;

[0094] (b) a polypeptide having at least 97.6% sequence identity to the polypeptide of SEQ ID NO: 24;

[0095] (c) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 27;

[0096] (d) a polypeptide having at least 90% sequence identity to the polypeptide of SEQ ID NO: 30;

[0097] (e) a polypeptide having at least 92% sequence identity to the polypeptide of SEQ ID NO: 36;

[0098] (f) a polypeptide having at least 86% sequence identity to the polypeptide of SEQ ID NO:48;

[0099] (g) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO:54;

[0100] (h) a polypeptide having at least 81% sequence identity to the polypeptide of SEQ ID NO: 60;

[0101] (i) a polypeptide having at least 84% sequence identity to the polypeptide of SEQ ID NO: 66;

[0102] (j) a polypeptide having at least 87% sequence identity to the polypeptide of SEQ ID NO: 105;

[0103] (k) a polypeptide having at least 85% sequence identity to the polypeptide of SEQ ID NO: 108;

[0104] (l) a polypeptide having at least 80% sequence identity with the polypeptide of SEQ ID NO: 114;

[0105] (m) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 120;

[0106] (n) a polypeptide having at least 89% sequence identity to the polypeptide of SEQ ID NO: 123;

[0107] (o) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 126;

[0108] (p) a polypeptide having at least 85% sequence identity to the polypeptide of SEQ ID NO: 138;

[0109] (q) a polypeptide having at least 89% sequence identity to the polypeptide of SEQ ID NO: 141;

[0110] (r) a polypeptide having at least 86% sequence identity to the polypeptide of SEQ ID NO: 147;

[0111] (s) a polypeptide having at least 96.4% sequence identity to the polypeptide of SEQ ID NO: 156;

[0112] (t) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 162;

[0113] (u) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 165;

[0114] (v) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 168;

[0115] (w) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 171;

[0116] (x) a polypeptide having at least 82% sequence identity to the polypeptide of SEQ ID NO: 174;

[0117] (y) a polypeptide encoded by a polynucleotide that hybridizes under high stringency conditions or very high stringency conditions to

[0118] (i) the mature polypeptide coding sequence of SEQ ID NO: 10,

[0119] (ii) the mature polypeptide coding sequence of SEQ ID NO: 22,

[0120] (iii) the mature polypeptide coding sequence of SEQ ID NO: 25,

[0121] (iv) the mature polypeptide coding sequence of SEQ ID NO: 28,

[0122] (v) the mature polypeptide coding sequence of SEQ ID NO:34,

[0123] (vi) the mature polypeptide coding sequence of SEQ ID NO:46,

[0124] (vii) the mature polypeptide coding sequence of SEQ ID NO:52,

[0125] (viii) the mature polypeptide coding sequence of SEQ ID NO:58,

[0126] (ix) the mature polypeptide coding sequence of SEQ ID NO: 64,

[0127] (x) the mature polypeptide coding sequence of SEQ ID NO: 103,

[0128] (xi) the mature polypeptide coding sequence of SEQ ID NO: 106,

[0129] (xii) the mature polypeptide coding sequence of SEQ ID NO: 112,

[0130] (xiii) the mature polypeptide coding sequence of SEQ ID NO: 118,

[0131] (xiv) the mature polypeptide coding sequence of SEQ ID NO: 121,

[0132] (xv) the mature polypeptide coding sequence of SEQ ID NO: 124,

[0133] (xvi) the mature polypeptide coding sequence of SEQ ID NO: 136,

[0134] (xvii) the mature polypeptide coding sequence of SEQ ID NO: 139,

[0135] (xviii) the mature polypeptide coding sequence of SEQ ID NO: 145,

[0136] (xix) the mature polypeptide coding sequence of SEQ ID NO: 154,

[0137] (xx) the mature polypeptide coding sequence of SEQ ID NO: 160,

[0138] (xxi) the mature polypeptide coding sequence of SEQ ID NO: 163,

[0139] (xxii) the mature polypeptide coding sequence of SEQ ID NO: 166,

[0140] (xxiii) the mature polypeptide coding sequence of SEQ ID NO: 169,

[0141] (xxiv) the mature polypeptide coding sequence of SEQ ID NO: 172,

[0142] (xxv) the full complementary strand of (i), (ii), (iii), (iv), (v), (vi), (vii), (viii), (ix), (x), (xi), (xii), (xiii), (xiv), (xv), (xvi), (xvii), (xviii), (xix), (xx), (xxi), (xxii), (xxiii), or (xxiv);

[0143] (z) a polypeptide encoded by a polynucleotide having at least 85% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 10;

[0144] (aa) a polypeptide encoded by the following polynucleotide, which has at least 97.6% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 22;

[0145] (ab) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 25;

[0146] (ac) a polypeptide encoded by a polynucleotide having at least 90% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 28;

[0147] (ad) a polypeptide encoded by the following polynucleotide, which has at least 92% sequence identity with the mature polypeptide coding sequence of SEQ ID NO:34;

[0148] (ae) a polypeptide encoded by a polynucleotide having at least 86% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 46;

[0149] (af) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:52;

[0150] (ag) a polypeptide encoded by a polynucleotide having at least 81% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 58;

[0151] (ah) a polypeptide encoded by the following polynucleotide, which has at least 84% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:64;

[0152] (ai) a polypeptide encoded by a polynucleotide having at least 87% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 103;

[0153] (aj) a polypeptide encoded by a polynucleotide having at least 85% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 106;

[0154] (ak) a polypeptide encoded by the following polynucleotide, which has at least 80% sequence identity with the mature polypeptide coding sequence of SEQ ID NO: 111;

[0155] (a1) a polypeptide encoded by the following polynucleotide, which has at least 80% sequence identity with the mature polypeptide coding sequence of SEQ ID NO: 118;

[0156] (am) a polypeptide encoded by the following polynucleotide, which has at least 89% sequence identity with the mature polypeptide coding sequence of SEQ ID NO: 121;

[0157] (an) a polypeptide encoded by the following polynucleotide, which has at least 80% sequence identity with the mature polypeptide coding sequence of SEQ ID NO: 124;

[0158] (ao) a polypeptide encoded by the following polynucleotide, which has at least 85% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 136;

[0159] (ap) a polypeptide encoded by a polynucleotide having at least 89% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 139;

[0160] (aq) a polypeptide encoded by the following polynucleotide, which has at least 86% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 145;

[0161] (ar) a polypeptide encoded by the following polynucleotide, which has at least 96.4% sequence identity with the mature polypeptide coding sequence of SEQ ID NO: 154;

[0162] (as) a polypeptide encoded by the following polynucleotide, which has at least 80% sequence identity with the mature polypeptide coding sequence of SEQ ID NO: 160;

[0163] (at) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 163;

[0164] (au) a polypeptide encoded by the following polynucleotide, which has at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 166;

[0165] (av) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 169;

[0166] (aw) a polypeptide encoded by a polynucleotide having at least 82% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 172;

[0167] (ax) a variant of SEQ ID NO: 12, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 or 45 position;

[0168] (ay) a variant of SEQ ID NO: 24, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions in 1, 2, 3, 4, 5, 6 or 7 positions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof;

[0169] (az) a variant of a polypeptide selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 54, SEQ ID NO: 60, SEQ ID NO: 108, SEQ ID NO: 114, SEQ ID NO: 120, SEQ ID NO: 126, SEQ ID NO: 162, SEQ ID NO: 165, SEQ ID NO: 168, SEQ ID NO: 171 or SEQ ID NO: 172. NO: 174, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 positions;

[0170] (ba) a variant of SEQ ID NO:30, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42 or 43 positions;

[0171] (bb) a variant of SEQ ID NO:36, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33 or 34 positions;

[0172] (bc) a variant of a polypeptide selected from the group consisting of SEQ ID NO:48 or SEQ ID NO:147, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 or 42 positions;

[0173] (bd) a variant of SEQ ID NO:66, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 or 48 positions;

[0174] (be) a variant of SEQ ID NO: 105, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 or 39 positions;

[0175] (bf) a variant of a polypeptide selected from the group consisting of SEQ ID NO: 123 or SEQ ID NO: 141, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 or 33 positions;

[0176] (bg) a variant of SEQ ID NO: 138, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 or 46 positions;

[0177] (bh) a variant of SEQ ID NO: 156, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 positions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof;

[0178] (bi) a polypeptide comprising the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w), (x), (y), (z), (aa), (ab), (ac), (ad), (ae), (af), (ag), (ah), (ai), (aj), (ak), (al), (am), (an), (ao), (ap), (aq), (ar), (as), (at), (au), (av), (aw), (ax), (ay), (az), (ba), (bb), (bc), (bd), (be), (bf), (bg) or (bh) and an N-terminal and / or C-terminal His-tag and / or HQ-tag;

[0179]

[0013] The invention further comprises a fragment of a polypeptide of the type A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z, Aa, Ab, Aca ...

[0180] 8. The polypeptide according to item 7, wherein the polypeptide comprises or consists of amino acids 1 to 303 of SEQ ID NO: 12, amino acids 1 to 302 of SEQ ID NO: 24, amino acids 1 to 309 of SEQ ID NO: 27, amino acids 1 to 438 of SEQ ID NO: 30, amino acids 1 to 446 of SEQ ID NO: 33, amino acids 1 to 438 of SEQ ID NO: 36, amino acids 1 to 446 of SEQ ID NO: 39, amino acids 1 to 302 of SEQ ID NO: 48, amino acids 1 to 311 of SEQ ID NO: 51, amino acids 1 to 364 of SEQ ID NO: 54, amino acids 1 to 373 of SEQ ID NO: 57, amino acids 1 to 436 of SEQ ID NO: 60,

[0181] amino acids 1 to 444 of SEQ ID NO:63, amino acids 1 to 302 of SEQ ID NO:66, amino acids 1 to 311 of SEQ ID NO:69, amino acids 1 to 302 of SEQ ID NO:105, amino acids 1 to 464 of SEQ ID NO:108, amino acids 1 to 472 of SEQ ID NO:111, amino acids 1 to 364 of SEQ ID NO:114, amino acids 1 to 372 of SEQ ID NO:117, amino acids 1 to 357 of SEQ ID NO:120, amino acids 1 to 302 of SEQ ID NO:123, amino acids 1 to 453 of SEQ ID NO:126, amino acids 1 to 461 of SEQ ID NO:129, amino acids 1 to 309 of SEQ ID NO:138, amino acids 1 to 304 of SEQ ID NO:141, amino acids 1 to 312 of SEQ ID NO:144, amino acids 1 to 302 of SEQ ID NO:147, amino acids 1 to 316 of SEQ ID NO:156, amino acids 1 to 303 of SEQ ID NO:162, amino acids 1 to 361 of SEQ ID NO:165, amino acids 1 to 373 of SEQ ID NO:168, amino acids 1 to 302 of SEQ ID NO:171, or amino acids 1 to 364 of SEQ ID NO:174.

[0182] 9. A composition comprising one or more polypeptides according to any one of items 7 to 8.

[0183] 10. The composition of item 9, further comprising one or more GH10 or GH11 polypeptides having xylanase activity.

[0184] 11. The composition of item 10, wherein the GH10 or GH11 polypeptide having xylanase activity is selected from the group consisting of:

[0185] (a) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 70;

[0186] (b) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 71;

[0187] (c) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 72;

[0188] (d) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 73;

[0189] (e) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 74;

[0190] (f) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 75;

[0191] (g) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 78;

[0192] (h) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 81;

[0193] (i) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 84;

[0194] (j) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 88;

[0195] (k) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 89;

[0196] (l) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO:95;

[0197] (m) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO:96;

[0198] (n) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO:99;

[0199] (o) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 102;

[0200] (p) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 177;

[0201] (q) a variant of a polypeptide selected from the group consisting of SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:78, SEQ ID NO:81, SEQ ID NO:84, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:99, SEQ ID NO:102, and SEQ ID NO:177, wherein the variant has xylanase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions in 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions, or any combination thereof;

[0202] (r) a polypeptide comprising the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p) or (q) and an N-terminal and / or C-terminal His-tag and / or HQ-tag; and

[0203] (s) (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q) or (r) The fragment has xylanase activity and has at least 90% of the length of the mature polypeptide.

[0204] 12. The composition according to item 11, wherein the GH10 or GH11 polypeptide having xylanase activity is selected from the group consisting of amino acids 1 to 384 of SEQ ID NO:70, amino acids 1 to 288 of SEQ ID NO:71, amino acids 1 to 308 of SEQ ID NO:72, amino acids 1 to 195 of SEQ ID NO:73, amino acids 1 to 203 of SEQ ID NO:74, amino acids 1 to 182 of SEQ ID NO:75, amino acids 1 to 183 of SEQ ID NO:78, amino acids 1 to 181 of SEQ ID NO:81, amino acids 1 to 299 of SEQ ID NO:84, amino acids 1 to 307 of SEQ ID NO:87, amino acids 1 to 188 of SEQ ID NO:88, amino acids 1 to 189 of SEQ ID NO:89, amino acids 1 to 328 of SEQ ID NO:95, amino acids 1 to 208 of SEQ ID NO:96, amino acids 1 to 203 of SEQ ID NO:99, amino acids 1 to 337 of SEQ ID NO:102, or amino acids 1 to 323 of SEQ ID NO:177.

[0205] 13. The composition of any one of items 1 to 6 or 9 to 12, further comprising one or more formulating agents, one or more additional enzymes and / or one or more microorganisms.

[0206] 14. An animal feed additive comprising the composition of any one of items 1 to 6 or 9 to 13 and one or more components selected from the following list, the list consisting of:

[0207] one or more vitamins;

[0208] one or more minerals;

[0209] one or more amino acids; and

[0210] one or more other feed ingredients.

[0211] 15. An animal feed comprising the composition of any one of items 1 to 6 or 9 to 13 or the animal feed additive of item 14 and a plant-based material from the subfamily Panicum.

[0212] 16. A method for improving one or more performance parameters of an animal, the method comprising administering to one or more animals the composition of any one of items 1 to 6 or 9 to 13, the animal feed additive of item 14, or the animal feed of item 15.

[0213] 17. A method of solubilizing xylose from a plant-based material, the method comprising treating the plant-based material from the subfamily Panicum with the composition of any one of items 1 to 6 or 9 to 13 or the animal feed additive of item 14.

[0214] 18. A method for releasing starch from a plant-based material, the method comprising treating the plant-based material from the subfamily Panicum with the composition of any one of items 1 to 6 or 9 to 13 or the animal feed additive of item 14.

[0215] 19. A method for improving the nutritional value of animal feed, the method comprising adding the composition according to any one of items 1 to 6 or 9 to 13 or the animal feed additive according to item 14 to the feed.

[0216] 20. A method for preparing an animal feed, the method comprising mixing the composition of any one of items 1 to 6 or 9 to 13 or the animal feed additive of item 14 with a plant-based material from the subfamily Panicum.

[0217] 21. Use of the composition according to any one of items 1 to 6 or 9 to 13, the animal feed additive according to item 14 or the animal feed according to item 15 in the following items:

[0218] in animal feed;

[0219] in animal feed additives;

[0220] In the preparation of a composition for animal feed;

[0221] For improving the nutritional value of animal feed;

[0222] Used to increase the digestibility of animal feed;

[0223] for improving one or more performance parameters in animals;

[0224] For releasing xylose from a plant-based material of the subfamily Panicum; and / or

[0225] For releasing starch from plant-based materials of the Panicum subfamily.

[0226] 22. An isolated polypeptide having xylanase activity, the isolated polypeptide being selected from the group consisting of:

[0227] (a) a polypeptide having at least 84% sequence identity to the polypeptide of SEQ ID NO: 84;

[0228] (b) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 99;

[0229] (c) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 102;

[0230] (d) a polypeptide encoded by a polynucleotide that hybridizes under high stringency conditions or very high stringency conditions to

[0231] (i) the mature polypeptide coding sequence of SEQ ID NO: 82,

[0232] (ii) the mature polypeptide coding sequence of SEQ ID NO:97,

[0233] (iii) the mature polypeptide coding sequence of SEQ ID NO: 100,

[0234] (iv) the full-length complementary strand of (i), (ii) or (iii);

[0235] (e) a polypeptide encoded by a polynucleotide having at least 84% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 82;

[0236] (f) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 97;

[0237] (g) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 100;

[0238] (h) a variant of a polypeptide selected from the group consisting of SEQ ID NO:84, SEQ ID NO:99 or SEQ ID NO:102, wherein the variant has xylanase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 positions;

[0239] (i) a polypeptide comprising the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h) or (i) and an N-terminal and / or C-terminal His-tag and / or HQ-tag; and

[0240] (j) a fragment of the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i) or (j), which fragment has xylanase activity and has at least 90% of the length of the mature polypeptide.

[0241] 23. The polypeptide according to item 22, wherein the polypeptide comprises or consists of amino acids 1 to 299 of SEQ ID NO: 84, amino acids 1 to 307 of SEQ ID NO: 87, amino acids 1 to 203 of SEQ ID NO: 99, or amino acids 1 to 337 of SEQ ID NO: 102.

[0242] 24. A composition comprising one or more polypeptides according to any one of items 22 to 23.

[0243] 25. The composition of item 24, further comprising one or more formulating agents, one or more additional enzymes and / or one or more microorganisms.

[0244] 26. An animal feed or an animal feed additive comprising the polypeptide according to any one of items 22 to 23 or the composition according to any one of items 24 to 25 and one or more components selected from the following list, the list consisting of:

[0245] one or more vitamins;

[0246] one or more minerals;

[0247] one or more amino acids;

[0248] one or more other feed ingredients; and

[0249] Plant-based material from the subfamily Panicum.

[0250] 27. A polynucleotide encoding the polypeptide according to any one of items 7 to 8 or 22 to 23.

[0251] 28. A nucleic acid construct or expression vector comprising the polynucleotide of item 27, which is operably linked to one or more control sequences that direct the production of the polypeptide in an expression host.

[0252] 29. A recombinant host cell comprising the polynucleotide of item 27, which is operably linked to one or more control sequences that direct the production of the polypeptide.

[0253] 30. A method for producing a polypeptide according to any one of items 7 to 8 or 22 to 23, the method comprising:

[0254] (a) cultivating the recombinant host cell of item 29 under conditions conducive to production of the polypeptide; and

[0255] (b) recovering the polypeptide.

[0256] Sequence Listing Overview

[0257] SEQ ID NO: 1 is the GH62 conserved motif:

[0258] [H / Y][L / M]F[F / S][A / C / H / S / T / V][A / D / G / N / R]D[D / E / N]G.

[0259] SEQ ID NO: 2 is the GH62 conserved motif: [H / Y]LF[F / S][A / S / V][A / D / G]DNG

[0260] SEQ ID NO: 3 is the GH62 conserved motif: YLFF[A / V][A / G]DNG

[0261] SEQ ID NO: 4 is the GH62 conserved motif: YLFFAGDNG

[0262] SEQ ID NO: 5 is the GH62 conserved motif: [H / Y]LFSSDDNG

[0263] SEQ ID NO:6 is the GH62 conserved motif: YLFSSDDNG

[0264] SEQ ID NO: 7 is the gene sequence of GH62 arabinofuranosidase as isolated from Penicillium capsulatum.

[0265] SEQ ID NO: 8 is the amino acid sequence as deduced from SEQ ID NO: 7 and as disclosed as SEQ ID NO: 2 in WO 2006 / 125438.

[0266] SEQ ID NO: 9 is the amino acid sequence of the mature GH62 arabinofuranosidase from Penicillium capsulatum.

[0267] SEQ ID NO: 10 is the gene sequence of GH62 arabinofuranosidase isolated from Penicillium fulvei.

[0268] SEQ ID NO:11 is the amino acid sequence as deduced from SEQ ID NO:10.

[0269] SEQ ID NO: 12 is the amino acid sequence of the mature GH62 arabinofuranosidase from Penicillium fulvum.

[0270] SEQ ID NO: 13 is the codon-optimized DNA sequence of the gene sequence Uniprot: XM_001273614 of the GH62 arabinofuranosidase isolated from Aspergillus clavatus.

[0271] SEQ ID NO: 14 is the amino acid sequence as deduced from SEQ ID NO: 13 (Uniprot: A1CCD2) and as disclosed as SEQ ID NO: 996 in WO2014 / 081884.

[0272] SEQ ID NO: 15 is the amino acid sequence of the mature GH62 arabinofuranosidase from Aspergillus clavatus.

[0273] SEQ ID NO: 16 is the codon-optimized DNA sequence of the gene sequence Uniprot: XM_001265651 of the GH62 arabinofuranosidase isolated from Neosartorya fischeri.

[0274] SEQ ID NO: 17 is the amino acid sequence as deduced from SEQ ID NO: 16 (Uniprot: A1CYD5) and as disclosed as SEQ ID NO: 1177 in WO2014 / 081884.

[0275] SEQ ID NO: 18 is the amino acid sequence of the mature GH62 arabinofuranosidase from Neosartorya fischeri.

[0276] SEQ ID NO: 19 is the codon-optimized DNA sequence of the gene sequence Uniprot: XM_755363 of the GH62 arabinofuranosidase isolated from Ustilago maydis (see Kaemper et al., Nature, 2006, 444, 97-101).

[0277] SEQ ID NO:20 is the amino acid sequence as deduced from SEQ ID NO:19 (Uniprot:Q4P6F4).

[0278] SEQ ID NO: 21 is the amino acid sequence of the mature GH62 arabinofuranosidase from Ustilago maydis.

[0279] SEQ ID NO: 22 is the gene sequence of GH62 arabinofuranosidase isolated from Penicillium oxalicum.

[0280] SEQ ID NO:23 is the amino acid sequence as deduced from SEQ ID NO:22.

[0281] SEQ ID NO: 24 is the amino acid sequence of the mature GH62 arabinofuranosidase from Penicillium oxalicum.

[0282] SEQ ID NO: 25 is the gene sequence of GH62 arabinofuranosidase isolated from Talaromyces pinophilus.

[0283] SEQ ID NO:26 is the amino acid sequence as deduced from SEQ ID NO:25.

[0284] SEQ ID NO: 27 is the amino acid sequence of the mature GH62 arabinofuranosidase from Talaromyces fulvidraco.

[0285] SEQ ID NO: 28 is the gene sequence of GH62 arabinofuranosidase as isolated from Streptomyces nitrosporeus.

[0286] SEQ ID NO:29 is the amino acid sequence as deduced from SEQ ID NO:28.

[0287] SEQ ID NO: 30 is the amino acid sequence of the mature GH62 arabinofuranosidase from Streptomyces nitrosporus.

[0288] SEQ ID NO:31 is the DNA sequence of the recombinant expression DNA sequence derived from SEQ ID NO:28 with a His-tag and a Savinase signal peptide.

[0289] SEQ ID NO:32 is the amino acid sequence as deduced from SEQ ID NO:31.

[0290] SEQ ID NO:33 is the amino acid sequence of the mature GH62 arabinofuranosidase obtained from SEQ ID NO:32.

[0291] SEQ ID NO:34 is the gene sequence of GH62 arabinofuranosidase isolated from Streptomyces beijiangensis.

[0292] SEQ ID NO:35 is the amino acid sequence as deduced from SEQ ID NO:34.

[0293] SEQ ID NO:36 is the amino acid sequence of the mature GH62 arabinofuranosidase from Streptomyces northern Xinjiang.

[0294] SEQ ID NO:37 is the DNA sequence of the recombinant expression DNA sequence derived from SEQ ID NO:34 with a His-tag and a Savinase signal peptide.

[0295] SEQ ID NO:38 is the amino acid sequence as deduced from SEQ ID NO:37.

[0296] SEQ ID NO:39 is the amino acid sequence of the mature GH62 arabinofuranosidase obtained from SEQ ID NO:38.

[0297] SEQ ID NO: 40 is the gene sequence of the GH62 arabinofuranosidase isolated from Aspergillus clavatus (see Fedorova et al., PLoS, 100046).

[0298] SEQ ID NO:41 is the amino acid sequence as deduced from SEQ ID NO:40.

[0299] SEQ ID NO:42 is the amino acid sequence of the mature GH62 arabinofuranosidase from Aspergillus clavatus.

[0300] SEQ ID NO:43 is the DNA sequence of the recombinantly expressed DNA sequence from SEQ ID NO:40 with a His-tag.

[0301] SEQ ID NO:44 is the amino acid sequence as deduced from SEQ ID NO:43.

[0302] SEQ ID NO:45 is the amino acid sequence of the mature GH62 arabinofuranosidase obtained from SEQ ID NO:44.

[0303] SEQ ID NO: 46 is the gene sequence of GH62 arabinofuranosidase as isolated from Aspergillus wentii.

[0304] SEQ ID NO:47 is the amino acid sequence as deduced from SEQ ID NO:46.

[0305] SEQ ID NO:48 is the amino acid sequence of the mature GH62 arabinofuranosidase from Aspergillus vincifolius.

[0306] SEQ ID NO:49 is the DNA sequence of the recombinantly expressed DNA sequence from SEQ ID NO:46 with a His-tag.

[0307] SEQ ID NO:50 is the amino acid sequence as deduced from SEQ ID NO:49.

[0308] SEQ ID NO:51 is the amino acid sequence of the mature GH62 arabinofuranosidase obtained from SEQ ID NO:50.

[0309] SEQ ID NO:52 is the gene sequence of the GH62 arabinofuranosidase as isolated from Acrophialophora fusispora.

[0310] SEQ ID NO:53 is the amino acid sequence as deduced from SEQ ID NO:52.

[0311] SEQ ID NO:54 is the amino acid sequence of the mature GH62 arabinofuranosidase from Thielavia spp.

[0312] SEQ ID NO:55 is the DNA sequence of the recombinantly expressed DNA sequence from SEQ ID NO:52 with a His-tag.

[0313] SEQ ID NO:56 is the amino acid sequence as deduced from SEQ ID NO:55.

[0314] SEQ ID NO:57 is the amino acid sequence of the mature GH62 arabinofuranosidase obtained from SEQ ID NO:56.

[0315] SEQ ID NO:58 is the gene sequence of GH62 arabinofuranosidase as isolated from Streptosporangium sp-60756.

[0316] SEQ ID NO:59 is the amino acid sequence as deduced from SEQ ID NO:58.

[0317] SEQ ID NO:60 is the amino acid sequence of the mature GH62 arabinofuranosidase from Neurospora sp.-60756.

[0318] SEQ ID NO:61 is the DNA sequence of the recombinant expression DNA sequence derived from SEQ ID NO:58 with a His-tag and a Savinase signal peptide.

[0319] SEQ ID NO:62 is the amino acid sequence as deduced from SEQ ID NO:61.

[0320] SEQ ID NO:63 is the amino acid sequence of the mature GH62 arabinofuranosidase obtained from SEQ ID NO:62.

[0321] SEQ ID NO: 64 is the gene sequence of the GH62 arabinofuranosidase as isolated from Acrophialophora fusispora.

[0322] SEQ ID NO:65 is the amino acid sequence as deduced from SEQ ID NO:64.

[0323] SEQ ID NO: 66 is the amino acid sequence of the mature GH62 arabinofuranosidase from Thielavia spp.

[0324] SEQ ID NO:67 is the DNA sequence of the recombinantly expressed DNA sequence from SEQ ID NO:64 with a His-tag.

[0325] SEQ ID NO:68 is the amino acid sequence as deduced from SEQ ID NO:67.

[0326] SEQ ID NO:69 is the amino acid sequence of the mature GH62 arabinofuranosidase obtained from SEQ ID NO:68.

[0327] SEQ ID NO: 70 is the amino acid sequence of the mature GH10 xylanase from Aspergillus aculeatus as disclosed as SEQ ID NO: 5 (Xyl II) in WO 1994 / 021785.

[0328] SEQ ID NO: 71 is the amino acid sequence of a mature GH10 xylanase from Clostridium acetobutylicum (Swissprot Q97TP5).

[0329] SEQ ID NO: 72 is the amino acid sequence of the mature GH10 xylanase from Aspergillus aculeatus as disclosed as SEQ ID NO: 8 in WO 2005 / 059084.

[0330] SEQ ID NO: 73 is the amino acid sequence of the mature GH11 xylanase from Thermomyces lanuginosus as disclosed as SEQ ID NO: 2 in WO 1996 / 23062.

[0331] SEQ ID NO: 74 is the amino acid sequence of the mature GH11 xylanase from Dictyoglobulus thermophilus as disclosed as SEQ ID NO: 305 of WO 2011 / 057140.

[0332] SEQ ID NO: 75 is the amino acid sequence of the mature GH11 xylanase from Paenibacillus pabuli as disclosed as SEQ ID NO: 2 in WO 2005 / 079585.

[0333] SEQ ID NO: 76 is the gene sequence of the GH11 xylanase isolated from Bacillus stearothermophilus.

[0334] SEQ ID NO:77 is the amino acid sequence as deduced from SEQ ID NO:76 (Swissprot: P45705).

[0335] SEQ ID NO: 78 is the amino acid sequence of the mature GH11 xylanase from Bacillus stearothermophilus.

[0336] SEQ ID NO:79 is a DNA sequence derived from SEQ ID NO:76 and a synthetic DNA sequence of a Savinase signal peptide.

[0337] SEQ ID NO:80 is the amino acid sequence as deduced from SEQ ID NO:79.

[0338] SEQ ID NO:81 is the amino acid sequence of the mature GH11 xylanase obtained from SEQ ID NO:80.

[0339] SEQ ID NO:82 is the gene sequence of GH11 xylanase isolated from Streptomyces northern Xinjiang.

[0340] SEQ ID NO:83 is the amino acid sequence as deduced from SEQ ID NO:88.

[0341] SEQ ID NO:84 is the amino acid sequence of the mature GH11 xylanase from Streptomyces northern Xinjiang.

[0342] SEQ ID NO:85 is the DNA sequence of the recombinant expression DNA sequence derived from SEQ ID NO:82 with a His-tag and a Savinase signal peptide.

[0343] SEQ ID NO:86 is the amino acid sequence as deduced from SEQ ID NO:85.

[0344] SEQ ID NO:87 is the amino acid sequence of the mature GH62 arabinofuranosidase obtained from SEQ ID NO:86.

[0345] SEQ ID NO: 88 is the amino acid sequence of the mature GH11 xylanase from Fusarium oxysporum (FoxXyn 6) as disclosed as SEQ ID NO: 8 in WO 2014 / 019220.

[0346] SEQ ID NO: 89 is the amino acid sequence of the mature GH11 xylanase from Aspergillus clavatus (AclXyn5) as disclosed as SEQ ID NO: 8 in WO 2014 / 020143.

[0347] SEQ ID NO:90 is the Bacillus lentus secretion signal.

[0348] SEQ ID NO:91 is His-tag RHHHHHHP.

[0349] SEQ ID NO:92 is His-tag HHHHHHPR.

[0350] SEQ ID NO: 93 is the amino acid sequence of the GH43 arabinofuranosidase from Humicola insolens as disclosed as SEQ ID NO: 1 in WO 2006 / 114095.

[0351] SEQ ID NO: 94 is the amino acid sequence of the GH51 arabinofuranosidase from Meripilus giganteus as disclosed as SEQ ID NO: 2 in WO 2006 / 114095.

[0352] SEQ ID NO: 95 is the amino acid sequence of the mature GH10 xylanase XynB from Thermotoga maritima MSB8 as disclosed as SEQ ID NO: 1 in WO 2013 / 068550.

[0353] SEQ ID NO: 96 is the amino acid sequence of the mature GH11 xylanase Xyl6 from Myceliophthora thermophila as disclosed as SEQ ID NO: 41 in WO 2009 / 018537.

[0354] SEQ ID NO: 97 is the gene sequence of GH11 xylanase isolated from Lasiodiplodia theobromae.

[0355] SEQ ID NO:98 is the amino acid sequence as deduced from SEQ ID NO:97.

[0356] SEQ ID NO:99 is the amino acid sequence of the mature GH11 xylanase from Psoralea corylifolia.

[0357] SEQ ID NO: 100 is the gene sequence of a GH10 xylanase as isolated from Ascobolus stictoideus.

[0358] SEQ ID NO:101 is the amino acid sequence as deduced from SEQ ID NO:100.

[0359] SEQ ID NO: 102 is the amino acid sequence of a mature GH10 xylanase from Ascobolus stictoideus.

[0360] SEQ ID NO: 103 is the gene sequence of the GH62 arabinofuranosidase as isolated from Drechslera sp.

[0361] SEQ ID NO:104 is the amino acid sequence as deduced from SEQ ID NO:104.

[0362] SEQ ID NO: 105 is the amino acid sequence of the mature GH62 arabinofuranosidase from Deinococcus sp.

[0363] SEQ ID NO: 106 is the gene sequence of GH62 arabinofuranosidase as isolated from Xylanibacterium sp-61981.

[0364] SEQ ID NO:107 is the amino acid sequence as deduced from SEQ ID NO:106.

[0365] SEQ ID NO: 108 is the amino acid sequence of the mature GH62 arabinofuranosidase from Xylanalyticum sp.-61981.

[0366] SEQ ID NO: 109 is the DNA sequence of the recombinantly expressed DNA sequence from SEQ ID NO: 106 with a His-tag.

[0367] SEQ ID NO:110 is the amino acid sequence as deduced from SEQ ID NO:109.

[0368] SEQ ID NO:111 is the amino acid sequence of the mature GH62 arabinofuranosidase obtained from SEQ ID NO:110.

[0369] SEQ ID NO: 112 is the gene sequence of the GH62 arabinofuranosidase isolated from Microdochium nivale.

[0370] SEQ ID NO:113 is the amino acid sequence as deduced from SEQ ID NO:112.

[0371] SEQ ID NO: 114 is the amino acid sequence of the mature GH62 arabinofuranosidase from Microdochium nivale.

[0372] SEQ ID NO: 115 is the DNA sequence of the recombinantly expressed DNA sequence from SEQ ID NO: 112 with a His-tag.

[0373] SEQ ID NO:116 is the amino acid sequence as deduced from SEQ ID NO:115.

[0374] SEQ ID NO:117 is the amino acid sequence of the mature GH62 arabinofuranosidase obtained from SEQ ID NO:116.

[0375] SEQ ID NO: 118 is the gene sequence of GH62 arabinofuranosidase as isolated from Humicola hyalothermophila.

[0376] SEQ ID NO:119 is the amino acid sequence as deduced from SEQ ID NO:118.

[0377] SEQ ID NO: 120 is the amino acid sequence of the mature GH62 arabinofuranosidase from Humicola thermophila.

[0378] SEQ ID NO: 121 is the gene sequence of GH62 arabinofuranosidase as isolated from Curvularia geniculata.

[0379] SEQ ID NO:122 is the amino acid sequence as deduced from SEQ ID NO:121.

[0380] SEQ ID NO: 123 is the amino acid sequence of the mature GH62 arabinofuranosidase from Curvularia genu

[0381] SEQ ID NO: 124 is the gene sequence of the GH62 arabinofuranosidase as isolated from Glycomyces rutgersensis.

[0382] SEQ ID NO:125 is the amino acid sequence as deduced from SEQ ID NO:124.

[0383] SEQ ID NO: 126 is the amino acid sequence of the mature GH62 arabinofuranosidase from Saccharomyces rootei.

[0384] SEQ ID NO: 127 is the DNA sequence of the recombinant expression DNA sequence derived from SEQ ID NO: 124 with a His-tag and a Savinase signal peptide.

[0385] SEQ ID NO:128 is the amino acid sequence as deduced from SEQ ID NO:127.

[0386] SEQ ID NO:129 is the amino acid sequence of the mature GH62 arabinofuranosidase obtained from SEQ ID NO:128.

[0387] SEQ ID NO: 130 is the gene sequence of GH62 arabinofuranosidase isolated from Coprinopsis cinerea as disclosed in Proc Natl Acad Sci USA, 2010 107: 11889-11894 and Biosci Biotechnol Biochem 2010 75: 342-345.

[0388] SEQ ID NO:131 is the amino acid sequence as deduced from SEQ ID NO:130.

[0389] SEQ ID NO: 132 is the amino acid sequence of the mature GH62 arabinofuranosidase from Coprinus cinereus.

[0390] SEQ ID NO: 133 is the DNA sequence of the recombinantly expressed DNA sequence from SEQ ID NO: 130 with a His-tag.

[0391] SEQ ID NO:134 is the amino acid sequence as deduced from SEQ ID NO:133.

[0392] SEQ ID NO:135 is the amino acid sequence of the mature GH62 arabinofuranosidase obtained from SEQ ID NO:134.

[0393] SEQ ID NO: 136 is the gene sequence of GH62 arabinofuranosidase as isolated from Aspergillus aculeatus.

[0394] SEQ ID NO:137 is the amino acid sequence as deduced from SEQ ID NO:136.

[0395] SEQ ID NO: 138 is the amino acid sequence of the mature GH62 arabinofuranosidase from Aspergillus aculeatus.

[0396] SEQ ID NO: 139 is the gene sequence of GH62 arabinofuranosidase as isolated from Remersonia thermophila.

[0397] SEQ ID NO:140 is the amino acid sequence as deduced from SEQ ID NO:139.

[0398] SEQ ID NO: 141 is the amino acid sequence of the mature GH62 arabinofuranosidase from R. thermophilus.

[0399] SEQ ID NO: 142 is the DNA sequence of the recombinantly expressed DNA sequence from SEQ ID NO: 139 with a His-tag.

[0400] SEQ ID NO:143 is the amino acid sequence as deduced from SEQ ID NO:142.

[0401] SEQ ID NO:144 is the amino acid sequence of the mature GH62 arabinofuranosidase obtained from SEQ ID NO:143.

[0402] SEQ ID NO: 145 is the gene sequence of GH62 arabinofuranosidase as isolated from Penicillium soppii.

[0403] SEQ ID NO:155 is the amino acid sequence as deduced from SEQ ID NO:145.

[0404] SEQ ID NO: 147 is the amino acid sequence of the mature GH62 arabinofuranosidase from Penicillium dimer.

[0405] SEQ ID NO: 148 is the gene sequence of the GH62 arabinofuranosidase isolated from Bipolaris sorokiniana.

[0406] SEQ ID NO:149 is the amino acid sequence as deduced from SEQ ID NO:148.

[0407] SEQ ID NO: 150 is the amino acid sequence of the mature GH62 arabinofuranosidase from Helicoverpa graminearum.

[0408] SEQ ID NO: 151 is the DNA sequence of the recombinantly expressed DNA sequence from SEQ ID NO: 148 with a His-tag.

[0409] SEQ ID NO:152 is the amino acid sequence as deduced from SEQ ID NO:151.

[0410] SEQ ID NO:153 is the amino acid sequence of the mature GH62 arabinofuranosidase obtained from SEQ ID NO:152.

[0411] SEQ ID NO: 154 is the gene sequence of the GH62 arabinofuranosidase as isolated from Aspergillus fumigatiaffinis.

[0412] SEQ ID NO:155 is the amino acid sequence as deduced from SEQ ID NO:154.

[0413] SEQ ID NO: 156 is the amino acid sequence of a mature GH62 arabinofuranosidase from a relative of Aspergillus fumigatus.

[0414] SEQ ID NO: 157 is the gene sequence of GH62 arabinofuranosidase isolated from Neosartorya fischeri as disclosed in "Genomic islands in the pathogenic filamentous fungus Aspergillus fumigatus" PLoS. DOI: 10.1371 / journal.pgen.1000046.

[0415] SEQ ID NO:158 is the amino acid sequence as deduced from SEQ ID NO:157.

[0416] SEQ ID NO: 159 is the amino acid sequence of the mature GH62 arabinofuranosidase from Neosartorya fischeri.

[0417] SEQ ID NO: 160 is the gene sequence of GH62 arabinofuranosidase as isolated from Thielavia arenaria.

[0418] SEQ ID NO:161 is the amino acid sequence as deduced from SEQ ID NO:160.

[0419] SEQ ID NO: 162 is the amino acid sequence of the mature GH62 arabinofuranosidase from Thielavia serrata.

[0420] SEQ ID NO: 163 is the gene sequence of GH62 arabinofuranosidase isolated from Chaetomium olivicolor.

[0421] SEQ ID NO:164 is the amino acid sequence as deduced from SEQ ID NO:163.

[0422] SEQ ID NO: 165 is the amino acid sequence of the mature GH62 arabinofuranosidase from Chaetomium chlororaphis.

[0423] SEQ ID NO: 166 is the gene sequence of GH62 arabinofuranosidase as isolated from Thielavia terricola.

[0424] SEQ ID NO:167 is the amino acid sequence as deduced from SEQ ID NO:166.

[0425] SEQ ID NO: 168 is the amino acid sequence of the mature GH62 arabinofuranosidase from Thielavia truncatula.

[0426] SEQ ID NO: 169 is the gene sequence of the GH62 arabinofuranosidase isolated from Thielavia spp.

[0427] SEQ ID NO:170 is the amino acid sequence as deduced from SEQ ID NO:169.

[0428] SEQ ID NO: 171 is the amino acid sequence of the mature GH62 arabinofuranosidase from Thielavia truncatula.

[0429] SEQ ID NO: 172 is the gene sequence of the GH62 arabinofuranosidase as isolated from Humicola sp.

[0430] SEQ ID NO:173 is the amino acid sequence as deduced from SEQ ID NO:172.

[0431] SEQ ID NO: 174 is the amino acid sequence of a mature GH62 arabinofuranosidase from Humicola sp.

[0432] SEQ ID NO: 175 is the gene sequence of a GH10 xylanase isolated from Ustilago maydis as disclosed in Nature, 2006 444: 97-101.

[0433] SEQ ID NO:176 is the amino acid sequence as deduced from SEQ ID NO:175.

[0434] SEQ ID NO: 177 is the amino acid sequence of the mature GH10 xylanase from Ustilago maydis

[0435] SEQ ID NO: 178 is the DNA sequence of the recombinantly expressed DNA sequence from SEQ ID NO: 175 with a His-tag.

[0436] SEQ ID NO:179 is the amino acid sequence as deduced from SEQ ID NO:178.

[0437] SEQ ID NO:180 is the amino acid sequence of the mature GH10 xylanase obtained from SEQ ID NO:179.

[0438] definition

[0439] Allelic variant: The term "allelic variant" means any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation is naturally produced by mutation and can lead to polymorphism within a population. Gene mutations can be silent (no change in the encoded polypeptide) or can encode a polypeptide with an altered amino acid sequence. An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.

[0440] Arabinofuranosidase: The term "arabinofuranosidase" means an α-L-arabinofuranoside arabinofuranohydrolase (EC 3.2.1.55) that catalyzes the hydrolysis of terminal non-reducing α-L-arabinofuranoside residues in α-L-arabinosides. The enzyme acts on α-L-arabinofuranosides, α-L-arabinans containing (1,3)- and / or (1,2)- and / or (1,5)-linkages, arabinoxylans, and arabinogalactans. α-L-arabinofuranosidase is also known as arabinosidase, α-arabinosidase, α-L-arabinosidase, α-arabinofuranosidase, polysaccharide α-L-arabinofuranosidase, α-L-arabinofuranoside hydrolase, L-arabinosidase, or α-L-arabinanase. Medium viscosity wheat arabinoxylan (Megazyme International Ireland, Ltd., Bray, Co. Wicklow, Ireland) can be used in 5 mg per ml of 100 mM sodium acetate (pH 5) in a total volume of 200 μl at 40°C for 30 minutes, followed by Arabinofuranosidase activity was determined by arabinose analysis using HPX-87H column chromatography (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

[0441] The arabinofuranosidase of the present invention has at least 50% of the arabinofuranosidase activity of one or more polypeptides selected from the following list, the list consisting of the following: SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:45, SEQ ID NO:48, SEQ ID NO:51, SEQ ID NO:54, SEQ ID NO:57, SEQ ID NO:60, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:105, SEQ ID NO:108, SEQ ID NO:111, SEQ ID NO:114, SEQ ID NO:117, SEQ ID NO:120, SEQ ID NO:123, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133, SEQ ID NO:134, SEQ ID NO:135 ID NO:129, SEQ ID NO:132, SEQ ID NO:135, SEQ ID NO:138, SEQ ID NO:141, SEQ ID NO:144, SEQ ID NO:147, SEQ ID NO:150, SEQ ID NO:153, SEQ ID NO:156, SEQ ID NO:159, SEQ ID NO:162, SEQ ID NO:165, SEQ ID NO:168, SEQ ID NO:171 and SEQ ID NO:174.In a preferred embodiment, the arabinofuranosidase of the present invention has at least 70% of the arabinofuranosidase activity of one or more polypeptides selected from the following list, the list consisting of the following: SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:45, SEQ ID NO:48, SEQ ID NO:51, SEQ ID NO:54, SEQ ID NO:57, SEQ ID NO:60, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:105, SEQ ID NO:108, SEQ ID NO:111, SEQ ID NO:114, SEQ ID NO:117, SEQ ID NO:120, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133 NO:126, SEQ ID NO:129, SEQ ID NO:132, SEQ ID NO:135, SEQ ID NO:138, SEQ ID NO:141, SEQ ID NO:144, SEQ ID NO:147, SEQ ID NO:150, SEQ ID NO:153, SEQ ID NO:156, SEQ ID NO:159, SEQ ID NO:162, SEQ ID NO:165, SEQ ID NO:168, SEQ ID NO:171 and SEQ ID NO:174.In a preferred embodiment, the arabinofuranosidase of the present invention has at least 80% of the arabinofuranosidase activity of one or more polypeptides selected from the following list, the list consisting of the following: SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:45, SEQ ID NO:48, SEQ ID NO:51, SEQ ID NO:54, SEQ ID NO:57, SEQ ID NO:60, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:105, SEQ ID NO:108, SEQ ID NO:111, SEQ ID NO:114, SEQ ID NO:117, SEQ ID NO:120, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133 NO:126, SEQ ID NO:129, SEQ ID NO:132, SEQ ID NO:135, SEQ ID NO:138, SEQ ID NO:141, SEQ ID NO:144, SEQ ID NO:147, SEQ ID NO:150, SEQ ID NO:153, SEQ ID NO:156, SEQ ID NO:159, SEQ ID NO:162, SEQ ID NO:165, SEQ ID NO:168, SEQ ID NO:171 and SEQ ID NO:174.In a preferred embodiment, the arabinofuranosidase of the present invention has at least 90% of the arabinofuranosidase activity of one or more polypeptides selected from the following list, the list consisting of the following items: SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:45, SEQ ID NO:48, SEQ ID NO:51, SEQ ID NO:54, SEQ ID NO:57, SEQ ID NO:60, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:105, SEQ ID NO:108, SEQ ID NO:111, SEQ ID NO:114, SEQ ID NO:117, SEQ ID NO:120, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125 NO:126, SEQ ID NO:129, SEQ ID NO:132, SEQ ID NO:135, SEQ ID NO:138, SEQ ID NO:141, SEQ ID NO:144, SEQ ID NO:147, SEQ ID NO:150, SEQ ID NO:153, SEQ ID NO:156, SEQ ID NO:159, SEQ ID NO:162, SEQ ID NO:165, SEQ ID NO:168, SEQ ID NO:171 and SEQ ID NO:174.In a preferred embodiment, the arabinofuranosidase of the present invention has at least 95% of the arabinofuranosidase activity of one or more polypeptides selected from the following list, the list consisting of the following: SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:42, SEQ ID NO:45, SEQ ID NO:48, SEQ ID NO:51, SEQ ID NO:54, SEQ ID NO:57, SEQ ID NO:60, SEQ ID NO:63, SEQ ID NO:66, SEQ ID NO:69, SEQ ID NO:105, SEQ ID NO:108, SEQ ID NO:111, SEQ ID NO:114, SEQ ID NO:117, SEQ ID NO:120, SEQ ID NO:123, SEQ ID NO:124, SEQ ID NO:125, SEQ ID NO:126, SEQ ID NO:127, SEQ ID NO:128, SEQ ID NO:129, SEQ ID NO:130, SEQ ID NO:131, SEQ ID NO:132, SEQ ID NO:133 NO:126, SEQ ID NO:129, SEQ ID NO:132, SEQ ID NO:135, SEQ ID NO:138, SEQ ID NO:141, SEQ ID NO:144, SEQ ID NO:147, SEQ ID NO:150, SEQ ID NO:153, SEQ ID NO:156, SEQ ID NO:159, SEQ ID NO:162, SEQ ID NO:165, SEQ ID NO:168, SEQ ID NO:171 and SEQ ID NO:174.

[0442] In a preferred embodiment, the arabinofuranosidase of the present invention has at least 50%, such as at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 100% of the arabinofuranosidase activity of SEQ ID NO: 111. In a preferred embodiment, the arabinofuranosidase of the present invention has at least 50%, such as at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 100% of the arabinofuranosidase activity of SEQ ID NO: 24.

[0443] Arabinoxylan-containing material: The term "arabinoxylan-containing material" means any material comprising arabinoxylan. Arabinoxylan is a hemicellulose found in the primary and secondary cell walls of plants, including wood and grains, which consists of a copolymer of two pentose sugars, arabinose and xylose. The arabinoxylan chain contains a large number of 1,4-linked xylose units. Many of the xylose units are substituted with 2-, 3- or 2,3-substituted arabinose residues.

[0444] Examples of arabinoxylan-containing materials are forages, grains, seeds and cereals (e.g. from corn, oats, rye, barley, wheat, whole or prepared by crushing, grinding, etc.), trees or hardwoods (such as poplar, willow, eucalyptus, palm, maple, birch), bamboo, herbaceous and / or woody energy crops, agricultural food and feed crops, animal feed products, cassava peels, cocoa pods, sugar cane, sugar beets, locust bean meal, vegetable or fruit pomace, wood waste, bark, wood shavings, sawdust, wood pulp, pulping waste liquor, waste paper, cardboard, construction and demolition wood waste, industrial or municipal wastewater solids or sludge, fertilizers, by-products from brewing and / or fermentation processes, wet distillers grains, dried distillers grains, grain bagasse, distillers grains and bagasse.

[0445] Forage as defined herein also includes coarse grains. Forage is fresh plant material, such as hay and silage from forage plants (grasses) and other forage plants (seaweed, sprouted cereals and legumes) or any combination thereof. Examples of forage plants are alfalfa (Medicago sativa), Lotus japonica, Brassica plants (e.g., kale, rapeseed (canola), rutabaga (Swede), radish), clover (e.g., Trifolium rapae, Trifolium rapae, Trifolium rapae), grasses (e.g., Bermuda grass, Bromus, pseudo-oat grass, fescue, heath grass, bluegrass, Miscanthus, orchard grass, ryegrass, switchgrass, Timothy-grass), corn (maize), millet, barley, oats, rye, sorghum, soybeans and wheat and vegetables (e.g., sugar beets). Crops suitable for silage are common grasses, clover, alfalfa, vetch, oats, rye and maize. Forage further includes crop residues from cereal products (e.g. corn stover, straw from wheat, barley, oats, rye and other cereals), residues from vegetables like beet tops, residues from oilseed products like stems and leaves from soybeans, rapeseed and other legumes, and parts from grain refining processes for animal or human consumption or from fuel production or other industries.

[0446] Whole grains are generally dry plant materials with high levels of fiber, such as fiber from seeds and grains and crop residues (eg, straw, copra, rice straw, husks, beet waste), bran, husks.

[0447] Preferred sources of arabinoxylan containing material are forages, roughages, seeds and cereals, sugar cane, sugar beets and wood pulp.

[0448] Weight gain: The term "weight gain" means the increase in live weight of an animal during a given period of time, eg, weight gain from day 1 to day 21.

[0449] cDNA: The term "cDNA" means a DNA molecule that can be prepared by reverse transcription from a mature, spliced ​​mRNA molecule obtained from a eukaryotic or prokaryotic cell. cDNA lacks intron sequences that may be present in the corresponding genomic DNA. The early, primary RNA transcript is a precursor to mRNA that is processed through a series of steps, including splicing, before appearing as mature, spliced ​​mRNA.

[0450] Coding sequence: The term "coding sequence" means a polynucleotide that directly specifies the amino acid sequence of a polypeptide. The boundaries of the coding sequence are generally determined by an open reading frame, which begins with a start codon (such as ATG, GTG or TTG) and ends with a stop codon (such as TAA, TAG or TGA). The coding sequence can be a genomic DNA, cDNA, synthetic DNA or a combination thereof.

[0451] Control sequences: The term "control sequences" means nucleic acid sequences necessary for the expression of a polynucleotide encoding a mature polypeptide of the present invention. Each control sequence may be native (i.e., from the same gene) or exogenous (i.e., from a different gene) to the polynucleotide encoding the polypeptide, or native or exogenous to each other. Such control sequences include, but are not limited to, leader sequences, polyadenylation sequences, propeptide sequences, promoters, signal peptide sequences, and transcription terminators. At a minimum, control sequences include promoters, and transcription and translation termination signals. For the purpose of introducing specific restriction sites that are conducive to connecting these control sequences to the coding region of a polynucleotide encoding a polypeptide, these control sequences may be provided with multiple linkers.

[0452] Expression: The term "expression" includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, and secretion.

[0453] Expression vector: The term "expression vector" means a linear or circular DNA molecule comprising a polynucleotide encoding a polypeptide and operably linked to control sequences that provide for its expression.

[0454] Feed conversion rate: The term "feed conversion rate" refers to the amount of feed fed to an animal to increase the animal's body weight by a specified amount. Improved feed conversion rate means a lower feed conversion rate. By "lower feed conversion rate" or "improved feed conversion rate", it is meant that the use of the feed additive composition in the feed results in a smaller amount of feed being fed to the animal to increase the animal's body weight by a specified amount, compared to the amount of feed required to increase the animal's body weight by the same amount when the feed does not include the feed additive composition.

[0455] Feed efficiency: The term "feed efficiency" refers to the amount of weight gain per unit of feed when an animal is fed either randomly or a specified amount of food over a period of time. "Increased feed efficiency" means that the use of a feed additive composition according to the present invention in a feed results in increased weight gain per unit of feed intake compared to an animal fed without the presence of the feed additive composition.

[0456] Fragment: The term "fragment" means a polypeptide having one or more (eg, several) amino acids missing from the amino and / or carboxyl terminus of a mature polypeptide or domain; wherein the fragment has arabinofuranosidase activity.

[0457] In one aspect, the fragment comprises at least 90% of the amino acids of the mature polypeptide, such as 272 amino acids (SEQ ID NO: 8 or 9), 273 amino acids (SEQ ID NO: 11 or 12), 344 amino acids (SEQ ID NO: 14 or 15), 340 amino acids (SEQ ID NO: 17 or 18), 280 amino acids (SEQ ID NO: 20 or 21), 272 amino acids (SEQ ID NO: 23 or 24), 278 amino acids (SEQ ID NO: 26 or 27), 394 amino acids (SEQ ID NO: 29 or 30), 401 amino acids (SEQ ID NO: 32 or 33), 394 amino acids (SEQ ID NO: 35 or 36), 401 amino acids (SEQ ID NO: 38 or 39), 286 amino acids (SEQ ID NO: 41 or 42), 293 amino acids (SEQ ID NO: 44 or 45), 272 amino acids (SEQ ID NO: 47 or 48), 280 amino acids (SEQ ID NO: 49 or 50), 512 amino acids (SEQ ID NO: 51 or 52), 513 amino acids (SEQ ID NO: 53 or 54), 514 amino acids (SEQ ID NO: 55 or 56), 515 amino acids (SEQ ID NO: 57 or 58), 516 amino acids (SEQ ID NO: 59 or 60), 520 amino acids (SEQ ID NO: 61 or 62), 634 amino acids (SEQ ID NO: 63 or 64), 635 amino acids (SEQ ID NO: 65 or 66), 636 amino acids (SEQ ID NO: NO: 50 or 51), 328 amino acids (SEQ ID NO: 53 or 54), 336 amino acids (SEQ ID NO: 56 or 57), 392 amino acids (SEQ ID NO: 59 or 60), 400 amino acids (SEQ ID NO: 62 or 63), 272 amino acids (SEQ ID NO: 65 or 66), 280 amino acids (SEQ ID NO: 68 or 69), 346 amino acids (SEQ ID NO: 70), 259 amino acids (SEQ ID NO: 71), 277 amino acids (SEQ ID NO: 72), 176 amino acids (SEQ ID NO: 73), 183 amino acids (SEQ ID NO: 74), 164 amino acids (SEQ ID NO: 75), 165 amino acids (SEQ ID NO: 77 or 78), 163 amino acids (SEQ ID NO: 80 or 81), 269 amino acids (SEQ ID NO: 83 or 84), 276 amino acids (SEQ ID NO: 85 or 86), NO: 86 or 87), 169 amino acids (SEQ ID NO: 88), 170 amino acids (SEQ ID NO: 89), 183 amino acids (SEQ ID NO: 98 or 99), 304 amino acids (SEQ ID NO: 101 or 102), 272 amino acids (SEQ ID NO: 104 or 105), 418 amino acids (SEQ ID NO: 107 or 108), 328 amino acids (SEQ ID NO: 113 or 114), 322 amino acids (SEQ ID NO: 119 or 120), 272 amino acids (SEQ ID NO: 121 or 122).NO: 122 or 123), 408 amino acids (SEQ ID NO: 125 or 126), 340 amino acids (SEQ ID NO: 131 or 132), 279 amino acids (SEQ ID NO: 137 or 138), 274 amino acids (SEQ ID NO: 140 or 141), 272 amino acids (SEQ ID NO: 146 or 147), 293 amino acids (SEQ ID NO: 148 or 149), 272 amino acids (SEQ ID NO: 149 or 150), 285 amino acids (SEQ ID NO: 155 or 156), 285 amino acids (SEQ ID NO: 158 or 159), 273 amino acids (SEQ ID NO: 161 or 162), 325 amino acids (SEQ ID NO: 164 or 165), 336 amino acids (SEQ ID NO: 167 or 168), 272 amino acids (SEQ ID NO: 168 or 169). NO: 170 or 171), 328 amino acids (SEQ ID NO: 173 or 174), or 291 amino acids (SEQ ID NO: 176 or 177).

[0458] In another aspect, the fragment comprises at least 92% of the amino acids of the mature polypeptide, such as 278 amino acids (SEQ ID NO: 8 or 9), 279 amino acids (SEQ ID NO: 11 or 12), 351 amino acids (SEQ ID NO: 14 or 15), 348 amino acids (SEQ ID NO: 17 or 18), 286 amino acids (SEQ ID NO: 20 or 21), 278 amino acids (SEQ ID NO: 23 or 24), 284 amino acids (SEQ ID NO: 26 or 27), 403 amino acids (SEQ ID NO: 29 or 30), 410 amino acids (SEQ ID NO: 32 or 33), 403 amino acids (SEQ ID NO: 35 or 36), 410 amino acids (SEQ ID NO: 38 or 39), 293 amino acids (SEQ ID NO: 41 or 42), 300 amino acids (SEQ ID NO: 44 or 45), 278 amino acids (SEQ ID NO: 47 or 48), 286 amino acids (SEQ ID NO: 49 or 50). NO: 50 or 51), 335 amino acids (SEQ ID NO: 53 or 54), 343 amino acids (SEQ ID NO: 56 or 57), 401 amino acids (SEQ ID NO: 59 or 60), 408 amino acids (SEQ ID NO: 62 or 63), 278 amino acids (SEQ ID NO: 65 or 66), 286 amino acids (SEQ ID NO: 68 or 69), 353 amino acids (SEQ ID NO: 70), 265 amino acids (SEQ ID NO: 71), 283 amino acids (SEQ ID NO: 72), 179 amino acids (SEQ ID NO: 73), 187 amino acids (SEQ ID NO: 74), 167 amino acids (SEQ ID NO: 75), 168 amino acids (SEQ ID NO: 77 or 78), 167 amino acids (SEQ ID NO: 80 or 81), 275 amino acids (SEQ ID NO: 83 or 84), 282 amino acids (SEQ ID NO: 85 or 86), 286 amino acids (SEQ ID NO: 87 or 88), 286 amino acids (SEQ ID NO: 89 or 90), 291 amino acids (SEQ ID NO: 91), 293 amino acids (SEQ ID NO: 92), 294 amino acids (SEQ ID NO: 93), 296 amino acids (SEQ ID NO: 94), 298 amino acids (SEQ ID NO: 95), 300 amino acids (SEQ ID NO: 101), 101 amino acids (SEQ ID NO: 102), 102 amino acids (SEQ ID NO: 103), 103 amino acids (SEQ ID NO: 104), 104 amino acids (SEQ ID NO: 105), 105 amino acids (SEQ ID NO: 106), 106 amino acids (SEQ ID NO: NO: 86 or 87), 173 amino acids (SEQ ID NO: 88), 174 amino acids (SEQ ID NO: 89), 187 amino acids (SEQ ID NO: 98 or 99), 311 amino acids (SEQ ID NO: 101 or 102), 278 amino acids (SEQ ID NO: 104 or 105), 427 amino acids (SEQ ID NO: 107 or 108), 335 amino acids (SEQ ID NO: 113 or 114), 329 amino acids (SEQ ID NO: 119 or 120), 278 amino acids (SEQ ID NO: 121 or 122), 309 amino acids (SEQ ID NO: 123 or 124), 310 amino acids (SEQ ID NO: 124 or 125), 311 amino acids (SEQ ID NO: 125 or 126), 313 amino acids (SEQ ID NO: 127 or 128), 314 amino acids (SEQ ID NO: 128 or 129), 315 amino acids (SEQ ID NO: 129 or 130), 316 amino acids (SEQ ID NO: 129 or 131), 317 amino acids (SEQ ID NO: 129 or 132), 318 amino acids (SEQ ID NO: 129 or 133), 319 amino acids (SEQ ID NO: 120 or 134), 319 amino acids (SEQ ID NO: 121 or 135), 318 amino acids (SEQ ID NO:NO: 122 or 123), 417 amino acids (SEQ ID NO: 125 or 126), 347 amino acids (SEQ ID NO: 131 or 132), 285 amino acids (SEQ ID NO: 137 or 138), 280 amino acids (SEQ ID NO: 140 or 141), 278 amino acids (SEQ ID NO: 146 or 147), 299 amino acids (SEQ ID NO: 148 or 149), 278 amino acids (SEQ ID NO: 149 or 150), 291 amino acids (SEQ ID NO: 155 or 156), 291 amino acids (SEQ ID NO: 158 or 159), 279 amino acids (SEQ ID NO: 161 or 162), 333 amino acids (SEQ ID NO: 164 or 165), 344 amino acids (SEQ ID NO: 167 or 168), 278 amino acids (SEQ ID NO: 169 or 170), 284 amino acids (SEQ ID NO: 171 or 172), 286 amino acids (SEQ ID NO: 173 or 174), 287 amino acids (SEQ ID NO: 175 or 176), 288 amino acids (SEQ ID NO: 177 or 178), 289 amino acids (SEQ ID NO: 180 or 181), 291 amino acids (SEQ ID NO: 182 or 183), 292 amino acids (SEQ ID NO: 184 or 185), 293 amino acids (SEQ ID NO: 186 or 187), 294 amino acids (SEQ ID NO: 188 or 189), 295 amino acids (SEQ ID NO: NO: 170 or 171), 335 amino acids (SEQ ID NO: 173 or 174), or 298 amino acids (SEQ ID NO: 176 or 177).

[0459] In another aspect, a fragment comprises at least 94% of the amino acids of a mature polypeptide, such as 284 amino acids (SEQ ID NO: 8 or 9), 285 amino acids (SEQ ID NO: 11 or 12), 359 amino acids (SEQ ID NO: 14 or 15), 355 amino acids (SEQ ID NO: 17 or 18), 292 amino acids (SEQ ID NO: 20 or 21), 284 amino acids (SEQ ID NO: 23 or 24), 290 amino acids (SEQ ID NO: 26 or 27), 412 amino acids (SEQ ID NO: 29 or 30), 419 amino acids (SEQ ID NO: 32 or 33), 412 amino acids (SEQ ID NO: 35 or 36), 419 amino acids (SEQ ID NO: 38 or 39), 299 amino acids (SEQ ID NO: 41 or 42), 306 amino acids (SEQ ID NO: 44 or 45), 284 amino acids (SEQ ID NO: 47 or 48), 292 amino acids (SEQ ID NO: 49 or 50). NO: 50 or 51), 342 amino acids (SEQ ID NO: 53 or 54), 351 amino acids (SEQ ID NO: 56 or 57), 410 amino acids (SEQ ID NO: 59 or 60), 417 amino acids (SEQ ID NO: 62 or 63), 284 amino acids (SEQ ID NO: 65 or 66), 292 amino acids (SEQ ID NO: 68 or 69), 361 amino acids (SEQ ID NO: 70), 271 amino acids (SEQ ID NO: 71), 290 amino acids (SEQ ID NO: 72), 183 amino acids (SEQ ID NO: 73), 191 amino acids (SEQ ID NO: 74), 171 amino acids (SEQ ID NO: 75), 172 amino acids (SEQ ID NO: 77 or 78), 170 amino acids (SEQ ID NO: 80 or 81), 281 amino acids (SEQ ID NO: 83 or 84), 289 amino acids (SEQ ID NO: 84 or 85). NO: 86 or 87), 177 amino acids (SEQ ID NO: 88), 178 amino acids (SEQ ID NO: 89), 191 amino acids (SEQ ID NO: 98 or 99), 317 amino acids (SEQ ID NO: 101 or 102), 284 amino acids (SEQ ID NO: 104 or 105), 437 amino acids (SEQ ID NO: 107 or 108), 343 amino acids (SEQ ID NO: 113 or 114), 336 amino acids (SEQ ID NO: 119 or 120), 284 amino acids (SEQ ID NO: 121 or 122).NO: 122 or 123), 426 amino acids (SEQ ID NO: 125 or 126), 355 amino acids (SEQ ID NO: 131 or 132), 291 amino acids (SEQ ID NO: 137 or 138), 286 amino acids (SEQ ID NO: 140 or 141), 284 amino acids (SEQ ID NO: 146 or 147), 306 amino acids (SEQ ID NO: 148 or 149), 284 amino acids (SEQ ID NO: 149 or 150), 298 amino acids (SEQ ID NO: 155 or 156), 298 amino acids (SEQ ID NO: 158 or 159), 285 amino acids (SEQ ID NO: 161 or 162), 340 amino acids (SEQ ID NO: 164 or 165), 351 amino acids (SEQ ID NO: 167 or 168), 284 amino acids (SEQ ID NO: 169 or 170), 298 amino acids (SEQ ID NO: 171 or 172), 298 amino acids (SEQ ID NO: 173 or 174), 298 amino acids (SEQ ID NO: 175 or 176), 298 amino acids (SEQ ID NO: 177 or 178), 298 amino acids (SEQ ID NO: 179 or 180), 298 amino acids (SEQ ID NO: 181 or 182), 298 amino acids (SEQ ID NO: 183 or 184), 298 amino acids (SEQ ID NO: 185 or 186), 298 amino acids (SEQ ID NO: NO: 170 or 171), 343 amino acids (SEQ ID NO: 173 or 174), or 304 amino acids (SEQ ID NO: 176 or 177).

[0460] In another aspect, a fragment comprises at least 96% of the amino acids of a mature polypeptide, such as 290 amino acids (SEQ ID NO: 8 or 9), 291 amino acids (SEQ ID NO: 11 or 12), 367 amino acids (SEQ ID NO: 14 or 15), 363 amino acids (SEQ ID NO: 17 or 18), 299 amino acids (SEQ ID NO: 20 or 21), 290 amino acids (SEQ ID NO: 23 or 24), 297 amino acids (SEQ ID NO: 26 or 27), 420 amino acids (SEQ ID NO: 29 or 30), 428 amino acids (SEQ ID NO: 32 or 33), 420 amino acids (SEQ ID NO: 35 or 36), 428 amino acids (SEQ ID NO: 38 or 39), 305 amino acids (SEQ ID NO: 41 or 42), 313 amino acids (SEQ ID NO: 44 or 45), 290 amino acids (SEQ ID NO: 47 or 48), 299 amino acids (SEQ ID NO: 49 or 50). NO: 50 or 51), 349 amino acids (SEQ ID NO: 53 or 54), 358 amino acids (SEQ ID NO: 56 or 57), 419 amino acids (SEQ ID NO: 59 or 60), 426 amino acids (SEQ ID NO: 62 or 63), 290 amino acids (SEQ ID NO: 65 or 66), 299 amino acids (SEQ ID NO: 68 or 69), 369 amino acids (SEQ ID NO: 70), 276 amino acids (SEQ ID NO: 71), 296 amino acids (SEQ ID NO: 72), 187 amino acids (SEQ ID NO: 73), 195 amino acids (SEQ ID NO: 74), 175 amino acids (SEQ ID NO: 75), 176 amino acids (SEQ ID NO: 77 or 78), 174 amino acids (SEQ ID NO: 80 or 81), 287 amino acids (SEQ ID NO: 83 or 84), 295 amino acids (SEQ ID NO: 86), 296 amino acids (SEQ ID NO: 87), 187 amino acids (SEQ ID NO: 88), 186 amino acids (SEQ ID NO: 89), 201 amino acids (SEQ ID NO: 100), 102 amino acids (SEQ ID NO: 101), 103 amino acids (SEQ ID NO: 102), 104 amino acids (SEQ ID NO: 103), 105 amino acids (SEQ ID NO: 104), 106 amino acids (SEQ ID NO: 105), 107 amino acids (SEQ ID NO: 106), 108 amino acids (SEQ ID NO: 107), 109 amino acids (SEQ ID NO: 110), 111 amino acids (SEQ ID NO: 112), 112 amino acids (SEQ ID NO: 113), 113 NO: 86 or 87), 180 amino acids (SEQ ID NO: 88), 181 amino acids (SEQ ID NO: 89), 195 amino acids (SEQ ID NO: 98 or 99), 324 amino acids (SEQ ID NO: 101 or 102), 290 amino acids (SEQ ID NO: 104 or 105), 446 amino acids (SEQ ID NO: 107 or 108), 350 amino acids (SEQ ID NO: 113 or 114), 343 amino acids (SEQ ID NO: 119 or 120), 290 amino acids (SEQ ID NO: 121 or 122).NO: 122 or 123), 435 amino acids (SEQ ID NO: 125 or 126), 362 amino acids (SEQ ID NO: 131 or 132), 297 amino acids (SEQ ID NO: 137 or 138), 292 amino acids (SEQ ID NO: 140 or 141), 290 amino acids (SEQ ID NO: 146 or 147), 312 amino acids (SEQ ID NO: 148 or 149), 290 amino acids (SEQ ID NO: 149 or 150), 304 amino acids (SEQ ID NO: 155 or 156), 304 amino acids (SEQ ID NO: 158 or 159), 291 amino acids (SEQ ID NO: 161 or 162), 347 amino acids (SEQ ID NO: 164 or 165), 359 amino acids (SEQ ID NO: 167 or 168), 290 amino acids (SEQ ID NO: 169 or 170). NO: 170 or 171), 350 amino acids (SEQ ID NO: 173 or 174), or 311 amino acids (SEQ ID NO: 176 or 177).

[0461] In another aspect, a fragment comprises at least 98% of the amino acids of a mature polypeptide, such as 296 amino acids (SEQ ID NO: 8 or 9), 297 amino acids (SEQ ID NO: 11 or 12), 374 amino acids (SEQ ID NO: 14 or 15), 370 amino acids (SEQ ID NO: 17 or 18), 305 amino acids (SEQ ID NO: 20 or 21), 296 amino acids (SEQ ID NO: 23 or 24), 303 amino acids (SEQ ID NO: 26 or 27), 429 amino acids (SEQ ID NO: 29 or 30), 437 amino acids (SEQ ID NO: 32 or 33), 429 amino acids (SEQ ID NO: 35 or 36), 437 amino acids (SEQ ID NO: 38 or 39), 312 amino acids (SEQ ID NO: 41 or 42), 319 amino acids (SEQ ID NO: 44 or 45), 296 amino acids (SEQ ID NO: 47 or 48), 305 amino acids (SEQ ID NO: 49 or 50), 512 amino acids (SEQ ID NO: 52 or 53), 512 amino acids (SEQ ID NO: 54 or 55), 512 amino acids (SEQ ID NO: 56 or 57), 512 amino acids (SEQ ID NO: 58 or 59), 524 amino acids (SEQ ID NO: 59 or 60), 525 amino acids (SEQ ID NO: 61 or 62), 526 amino acids (SEQ ID NO: 63 or 64), 527 amino acids (SEQ ID NO: 65 or 66), 528 amino acids (SEQ ID NO: 67 or 68), 529 amino acids (SEQ ID NO: NO: 50 or 51), 357 amino acids (SEQ ID NO: 53 or 54), 366 amino acids (SEQ ID NO: 56 or 57), 427 amino acids (SEQ ID NO: 59 or 60), 435 amino acids (SEQ ID NO: 62 or 63), 296 amino acids (SEQ ID NO: 65 or 66), 305 amino acids (SEQ ID NO: 68 or 69), 376 amino acids (SEQ ID NO: 70), 282 amino acids (SEQ ID NO: 71), 302 amino acids (SEQ ID NO: 72), 191 amino acids (SEQ ID NO: 73), 199 amino acids (SEQ ID NO: 74), 178 amino acids (SEQ ID NO: 75), 179 amino acids (SEQ ID NO: 77 or 78), 177 amino acids (SEQ ID NO: 80 or 81), 293 amino acids (SEQ ID NO: 83 or 84), 301 amino acids (SEQ ID NO: 85 or 86). NO: 86 or 87), 184 amino acids (SEQ ID NO: 88), 185 amino acids (SEQ ID NO: 89), 199 amino acids (SEQ ID NO: 98 or 99), 331 amino acids (SEQ ID NO: 101 or 102), 296 amino acids (SEQ ID NO: 104 or 105), 455 amino acids (SEQ ID NO: 107 or 108), 357 amino acids (SEQ ID NO: 113 or 114), 350 amino acids (SEQ ID NO: 119 or 120), 296 amino acids (SEQ ID NO: 121 or 122), 331 amino acids (SEQ ID NO: 123 or 124), 331 amino acids (SEQ ID NO: 124 or 125), 331 amino acids (SEQ ID NO: 125 or 126), 331 amino acids (SEQ ID NO: 127 or 128), 331 amino acids (SEQ ID NO: 128 or 129), 331 amino acids (SEQ ID NO: 129 or 130), 331 amino acids (SEQ ID NO: 121 or 131), 331 amino acids (SEQ ID NO: 129 or 132), 331 amino acids (SEQ ID NO: 129NO: 122 or 123), 444 amino acids (SEQ ID NO: 125 or 126), 370 amino acids (SEQ ID NO: 131 or 132), 303 amino acids (SEQ ID NO: 137 or 138), 298 amino acids (SEQ ID NO: 140 or 141), 296 amino acids (SEQ ID NO: 146 or 147), 319 amino acids (SEQ ID NO: 148 or 149), 296 amino acids (SEQ ID NO: 149 or 150), 310 amino acids (SEQ ID NO: 155 or 156), 310 amino acids (SEQ ID NO: 158 or 159), 297 amino acids (SEQ ID NO: 161 or 162), 354 amino acids (SEQ ID NO: 164 or 165), 366 amino acids (SEQ ID NO: 167 or 168), 296 amino acids (SEQ ID NO: 168 or 169). NO: 170 or 171), 357 amino acids (SEQ ID NO: 173 or 174), or 317 amino acids (SEQ ID NO: 176 or 177).

[0462] In another aspect, a fragment comprises at least 99% of the amino acids of a mature polypeptide, such as 299 amino acids (SEQ ID NO: 8 or 9), 300 amino acids (SEQ ID NO: 11 or 12), 378 amino acids (SEQ ID NO: 14 or 15), 374 amino acids (SEQ ID NO: 17 or 18), 308 amino acids (SEQ ID NO: 20 or 21), 299 amino acids (SEQ ID NO: 23 or 24), 306 amino acids (SEQ ID NO: 26 or 27), 434 amino acids (SEQ ID NO: 29 or 30), 442 amino acids (SEQ ID NO: 32 or 33), 434 amino acids (SEQ ID NO: 35 or 36), 442 amino acids (SEQ ID NO: 38 or 39), 315 amino acids (SEQ ID NO: 41 or 42), 323 amino acids (SEQ ID NO: 44 or 45), 299 amino acids (SEQ ID NO: 47 or 48), 308 amino acids (SEQ ID NO: 49 or 50). NO: 50 or 51), 360 amino acids (SEQ ID NO: 53 or 54), 369 amino acids (SEQ ID NO: 56 or 57), 432 amino acids (SEQ ID NO: 59 or 60), 440 amino acids (SEQ ID NO: 62 or 63), 299 amino acids (SEQ ID NO: 65 or 66), 308 amino acids (SEQ ID NO: 68 or 69), 380 amino acids (SEQ ID NO: 70), 285 amino acids (SEQ ID NO: 71), 305 amino acids (SEQ ID NO: 72), 193 amino acids (SEQ ID NO: 73), 201 amino acids (SEQ ID NO: 74), 180 amino acids (SEQ ID NO: 75), 181 amino acids (SEQ ID NO: 77 or 78), 179 amino acids (SEQ ID NO: 80 or 81), 296 amino acids (SEQ ID NO: 83 or 84), 304 amino acids (SEQ ID NO: 85 or 86), NO: 86 or 87), 186 amino acids (SEQ ID NO: 88), 187 amino acids (SEQ ID NO: 89), 201 amino acids (SEQ ID NO: 98 or 99), 334 amino acids (SEQ ID NO: 101 or 102), 299 amino acids (SEQ ID NO: 104 or 105), 460 amino acids (SEQ ID NO: 107 or 108), 361 amino acids (SEQ ID NO: 113 or 114), 354 amino acids (SEQ ID NO: 119 or 120), 299 amino acids (SEQ ID NO: 121 or 122).NO: 122 or 123), 449 amino acids (SEQ ID NO: 125 or 126), 374 amino acids (SEQ ID NO: 131 or 132), 306 amino acids (SEQ ID NO: 137 or 138), 301 amino acids (SEQ ID NO: 140 or 141), 299 amino acids (SEQ ID NO: 146 or 147), 322 amino acids (SEQ ID NO: 148 or 149), 299 amino acids (SEQ ID NO: 149 or 150), 313 amino acids (SEQ ID NO: 155 or 156), 313 amino acids (SEQ ID NO: 158 or 159), 300 amino acids (SEQ ID NO: 161 or 162), 358 amino acids (SEQ ID NO: 164 or 165), 370 amino acids (SEQ ID NO: 167 or 168), 299 amino acids (SEQ ID NO: 169 or 170). NO: 170 or 171), 361 amino acids (SEQ ID NO: 173 or 174) or 320 amino acids (SEQ ID NO: 176 or 177).

[0463] Highly branched xylan: The term "highly branched xylan" means that more than 50% of the xylose units in the arabinoxylan backbone are substituted. This is preferably calculated from linkage analysis as performed in Huismann et al., Carbohydrate Polymers, 2000, 42: 269-279.

[0464] Host cell: The term "host cell" means any cell type that is susceptible to transformation, transfection, transduction, etc. with a nucleic acid construct or expression vector comprising a polynucleotide of the present invention. The term "host cell" encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.

[0465] Isolated: The term "isolated" means a substance in a form or environment that does not exist in nature. Non-limiting examples of isolated substances include: (1) any non-naturally occurring substance; (2) any substance that is at least partially removed from one or more or all of the naturally occurring components with which it is naturally associated, including but not limited to any enzyme, variant, nucleic acid, protein, peptide, or cofactor; (3) any substance that has been artificially modified relative to that substance found in nature; or (4) any substance that has been modified by increasing the amount of the substance relative to other components with which it is naturally associated (e.g., recombinant production in a host cell; multiple copies of a gene encoding the substance; and the use of a stronger promoter than the promoter naturally associated with the gene encoding the substance).

[0466] Mature polypeptide: The term "mature polypeptide" means a polypeptide in its final form after translation and any post-translational modifications, such as N-terminal processing, C-terminal truncation, glycosylation, phosphorylation, and the like.

[0467] In one aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO:8, and amino acids -26 to -1 of SEQ ID NO:2 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO:9.

[0468] In one aspect, the mature polypeptide is amino acids 1 to 303 of SEQ ID NO: 11, and amino acids -26 to -1 of SEQ ID NO: 11 are a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 303 of SEQ ID NO:12.

[0469] In one aspect, the mature polypeptide is amino acids 1 to 382 of SEQ ID NO: 14, and amino acids -21 to -1 of SEQ ID NO: 15 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 382 of SEQ ID NO: 15.

[0470] In one aspect, the mature polypeptide is amino acids 1 to 378 of SEQ ID NO: 17, and amino acids -17 to -1 of SEQ ID NO: 17 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 378 of SEQ ID NO: 18.

[0471] In one aspect, the mature polypeptide is amino acids 1 to 311 of SEQ ID NO:20, and amino acids -20 to -1 of SEQ ID NO:20 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 311 of SEQ ID NO:21.

[0472] In one aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO: 23, and amino acids -29 to -1 of SEQ ID NO: 23 are a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO: 24.

[0473] In one aspect, the mature polypeptide is amino acids 1 to 309 of SEQ ID NO: 26, and amino acids -16 to -1 of SEQ ID NO: 26 are a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 309 of SEQ ID NO: 27.

[0474] In one aspect, the mature polypeptide is amino acids 1 to 438 of SEQ ID NO:29, and amino acids -36 to -1 of SEQ ID NO:29 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 438 of SEQ ID NO:30. In one aspect, the mature polypeptide is amino acids 1 to 446 of SEQ ID NO:32, and amino acids -27 to -1 of SEQ ID NO:32 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 446 of SEQ ID NO:33.

[0475] In one aspect, the mature polypeptide is amino acids 1 to 438 of SEQ ID NO:35, and amino acids -36 to -1 of SEQ ID NO:35 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 438 of SEQ ID NO:36. In one aspect, the mature polypeptide is amino acids 1 to 446 of SEQ ID NO:38, and amino acids -27 to -1 of SEQ ID NO:38 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 446 of SEQ ID NO:39.

[0476] In one aspect, the mature polypeptide is amino acids 1 to 318 of SEQ ID NO:41, and amino acids -18 to -1 of SEQ ID NO:41 are a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 318 of SEQ ID NO:42. In one aspect, the mature polypeptide is amino acids 1 to 326 of SEQ ID NO:44, and amino acids -18 to -1 of SEQ ID NO:44 are a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 326 of SEQ ID NO:45.

[0477] In one aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO:47, and amino acids -25 to -1 of SEQ ID NO:47 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO:48. In one aspect, the mature polypeptide is amino acids 1 to 311 of SEQ ID NO:50, and amino acids -25 to -1 of SEQ ID NO:50 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 311 of SEQ ID NO:51.

[0478] In one aspect, the mature polypeptide is amino acids 1 to 364 of SEQ ID NO:53, and amino acids -24 to -1 of SEQ ID NO:53 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 364 of SEQ ID NO:54. In one aspect, the mature polypeptide is amino acids 1 to 373 of SEQ ID NO:56, and amino acids -24 to -1 of SEQ ID NO:56 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 373 of SEQ ID NO:57.

[0479] In one aspect, the mature polypeptide is amino acids 1 to 436 of SEQ ID NO:59, and amino acids -31 to -1 of SEQ ID NO:59 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 436 of SEQ ID NO:60. In one aspect, the mature polypeptide is amino acids 1 to 444 of SEQ ID NO:62, and amino acids -27 to -1 of SEQ ID NO:62 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 444 of SEQ ID NO:63.

[0480] In one aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO: 65, and amino acids -19 to -1 of SEQ ID NO: 65 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO: 66. In one aspect, the mature polypeptide is amino acids 1 to 311 of SEQ ID NO: 68, and amino acids -19 to -1 of SEQ ID NO: 68 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 311 of SEQ ID NO: 69.

[0481] In one aspect, the mature polypeptide is amino acids 1 to 183 of SEQ ID NO: 77, and amino acids -27 to -1 of SEQ ID NO: 77 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO: 78. In one aspect, the mature polypeptide is amino acids 1 to 181 of SEQ ID NO: 80, and amino acids -27 to -1 of SEQ ID NO: 80 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 181 of SEQ ID NO: 81.

[0482] In one aspect, the mature polypeptide is amino acids 1 to 299 of SEQ ID NO: 83, and amino acids -42 to -1 of SEQ ID NO: 83 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 299 of SEQ ID NO: 84. In one aspect, the mature polypeptide is amino acids 1 to 307 of SEQ ID NO: 86, and amino acids -27 to -1 of SEQ ID NO: 86 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 307 of SEQ ID NO: 87.

[0483] In one aspect, the mature polypeptide is amino acids 1 to 203 of SEQ ID NO: 98, and amino acids -19 to -1 of SEQ ID NO: 98 are a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 203 of SEQ ID NO: 99.

[0484] In one aspect, the mature polypeptide is amino acids 1 to 337 of SEQ ID NO: 101, and amino acids -18 to -1 of SEQ ID NO: 101 are a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 337 of SEQ ID NO: 102.

[0485] In one aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO: 104, and amino acids -24 to -1 of SEQ ID NO: 104 are a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO: 105.

[0486] In one aspect, the mature polypeptide is amino acids 1 to 464 of SEQ ID NO: 107, and amino acids -36 to -1 of SEQ ID NO: 107 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 464 of SEQ ID NO: 108. In one aspect, the mature polypeptide is amino acids 1 to 472 of SEQ ID NO: 110, and amino acids -27 to -1 of SEQ ID NO: 110 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 472 of SEQ ID NO: 111.

[0487] In one aspect, the mature polypeptide is amino acids 1 to 364 of SEQ ID NO: 113, and amino acids -18 to -1 of SEQ ID NO: 113 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 364 of SEQ ID NO: 114. In one aspect, the mature polypeptide is amino acids 1 to 372 of SEQ ID NO: 116, and amino acids -18 to -1 of SEQ ID NO: 116 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 372 of SEQ ID NO: 117.

[0488] In one aspect, the mature polypeptide is amino acids 1 to 357 of SEQ ID NO: 119, and amino acids -27 to -1 of SEQ ID NO: 119 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 357 of SEQ ID NO: 120.

[0489] In one aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO: 122, and amino acids -24 to -1 of SEQ ID NO: 122 are a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO: 123.

[0490] In one aspect, the mature polypeptide is amino acids 1 to 453 of SEQ ID NO: 125, and amino acids -39 to -1 of SEQ ID NO: 125 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 453 of SEQ ID NO: 126. In one aspect, the mature polypeptide is amino acids 1 to 461 of SEQ ID NO: 128, and amino acids -27 to -1 of SEQ ID NO: 128 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 461 of SEQ ID NO: 129.

[0491] In one aspect, the mature polypeptide is amino acids 1 to 377 of SEQ ID NO: 131, and amino acids -20 to -1 of SEQ ID NO: 131 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 377 of SEQ ID NO: 132. In one aspect, the mature polypeptide is amino acids 1 to 385 of SEQ ID NO: 134, and amino acids -20 to -1 of SEQ ID NO: 134 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 385 of SEQ ID NO: 135.

[0492] In one aspect, the mature polypeptide is amino acids 1 to 309 of SEQ ID NO: 137, and amino acids -26 to -1 of SEQ ID NO: 137 are a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 309 of SEQ ID NO: 138.

[0493] In one aspect, the mature polypeptide is amino acids 1 to 304 of SEQ ID NO: 140, and amino acids -21 to -1 of SEQ ID NO: 140 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 304 of SEQ ID NO: 141. In one aspect, the mature polypeptide is amino acids 1 to 312 of SEQ ID NO: 143, and amino acids -21 to -1 of SEQ ID NO: 143 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 312 of SEQ ID NO: 144.

[0494] In one aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO: 146, and amino acids -26 to -1 of SEQ ID NO: 146 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO: 147.

[0495] In one aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO: 149, and amino acids -23 to -1 of SEQ ID NO: 149 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO: 150. In one aspect, the mature polypeptide is amino acids 1 to 310 of SEQ ID NO: 152, and amino acids -23 to -1 of SEQ ID NO: 152 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 310 of SEQ ID NO: 153.

[0496] In one aspect, the mature polypeptide is amino acids 1 to 316 of SEQ ID NO: 155, and amino acids -26 to -1 of SEQ ID NO: 155 are a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 316 of SEQ ID NO: 156.

[0497] In one aspect, the mature polypeptide is amino acids 1 to 316 of SEQ ID NO: 158, and amino acids -15 to -1 of SEQ ID NO: 158 are a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 316 of SEQ ID NO: 159.

[0498] In one aspect, the mature polypeptide is amino acids 1 to 303 of SEQ ID NO: 161, and amino acids -16 to -1 of SEQ ID NO: 161 are a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 303 of SEQ ID NO: 162.

[0499] In one aspect, the mature polypeptide is amino acids 1 to 361 of SEQ ID NO: 164, and amino acids -27 to -1 of SEQ ID NO: 164 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 361 of SEQ ID NO: 165.

[0500] In one aspect, the mature polypeptide is amino acids 1 to 373 of SEQ ID NO: 167, and amino acids -24 to -1 of SEQ ID NO: 167 are a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 373 of SEQ ID NO: 168.

[0501] In one aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO: 170, and amino acids -22 to -1 of SEQ ID NO: 170 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 302 of SEQ ID NO: 171.

[0502] In one aspect, the mature polypeptide is amino acids 1 to 364 of SEQ ID NO: 173, and amino acids -19 to -1 of SEQ ID NO: 173 are a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 364 of SEQ ID NO: 174.

[0503] In one aspect, the mature polypeptide is amino acids 1 to 323 of SEQ ID NO: 176, and amino acids -21 to -1 of SEQ ID NO: 176 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 323 of SEQ ID NO: 177. In one aspect, the mature polypeptide is amino acids 1 to 331 of SEQ ID NO: 179, and amino acids -21 to -1 of SEQ ID NO: 179 is a signal peptide. In another aspect, the mature polypeptide is amino acids 1 to 331 of SEQ ID NO: 180.

[0504] It is known in the art that a host cell can produce a mixture of two or more different mature polypeptides (i.e., having a different C-terminal and / or N-terminal amino acid) expressed by the same polynucleotide. It is also known in the art that different host cells process polypeptides differently, and thus a host cell expressing a polynucleotide can produce a different mature polypeptide (e.g., having a different C-terminal and / or N-terminal amino acid) when compared to another host cell expressing the same polynucleotide.

[0505] Mature polypeptide coding sequence: The term "mature polypeptide coding sequence" means a polynucleotide encoding a mature polypeptide having arabinofuranosidase or xylanase activity. In one aspect, the mature polypeptide coding sequence is nucleotides 79 to 987 of SEQ ID NO: 10; nucleotides 1 to 78 of SEQ ID NO: 10 encode a signal peptide.

[0506] In one aspect, the mature polypeptide coding sequence is a combination of nucleotides 49 to 70 and nucleotides 123 to 1027 of SEQ ID NO: 25 or its cDNA sequence; nucleotides 1 to 48 of SEQ ID NO: 25 encode a signal peptide.

[0507] In one aspect, the mature polypeptide coding sequence is nucleotides 88 to 993 of SEQ ID NO:22; nucleotides 1 to 87 of SEQ ID NO:22 encode the signal peptide.

[0508] In one aspect, the mature polypeptide coding sequence is nucleotides 109 to 1422 of SEQ ID NO:28; nucleotides 1 to 108 of SEQ ID NO:28 encode the signal peptide.

[0509] In one aspect, the mature polypeptide coding sequence is nucleotides 82 to 1419 of SEQ ID NO:31; nucleotides 1 to 81 of SEQ ID NO:31 encode the signal peptide.

[0510] In one aspect, the mature polypeptide coding sequence is nucleotides 109 to 1422 of SEQ ID NO:34; nucleotides 1 to 108 of SEQ ID NO:34 encode the signal peptide.

[0511] In one aspect, the mature polypeptide coding sequence is nucleotides 82 to 1419 of SEQ ID NO:37; nucleotides 1 to 81 of SEQ ID NO:37 encode the signal peptide.

[0512] In one aspect, the mature polypeptide coding sequence is nucleotides 76 to 981 of SEQ ID NO:46; nucleotides 1 to 75 of SEQ ID NO:46 encode the signal peptide.

[0513] In one aspect, the mature polypeptide coding sequence is nucleotides 76 to 1008 of SEQ ID NO:49; nucleotides 1 to 75 of SEQ ID NO:49 encode the signal peptide.

[0514] In one aspect, the mature polypeptide coding sequence is a combination of nucleotides 73 to 318, nucleotides 470 to 1298, and nucleotides 1392 to 1408 of SEQ ID NO:52; nucleotides 1 to 72 of SEQ ID NO:52 encode a signal peptide.

[0515] In one aspect, the mature polypeptide coding sequence is the combination of nucleotides 73 to 318, nucleotides 470 to 1298, and nucleotides 1392 to 1435 of SEQ ID NO:55; nucleotides 1 to 72 of SEQ ID NO:55 encode a signal peptide.

[0516] In one aspect, the mature polypeptide coding sequence is nucleotides 94 to 1401 of SEQ ID NO:58; nucleotides 1 to 93 of SEQ ID NO:58 encode the signal peptide.

[0517] In one aspect, the mature polypeptide coding sequence is nucleotides 82 to 1413 of SEQ ID NO:61; nucleotides 1 to 81 of SEQ ID NO:61 encode the signal peptide.

[0518] In one aspect, the mature polypeptide coding sequence is a combination of nucleotides 58 to 330, nucleotides 403 to 655, nucleotides 795 to 948, and nucleotides 1100 to 1325 of SEQ ID NO: 64; nucleotides 1 to 57 of SEQ ID NO: 64 encode a signal peptide.

[0519] In one aspect, the mature polypeptide coding sequence is the combination of nucleotides 58 to 330, nucleotides 403 to 655, nucleotides 795 to 948, and nucleotides 1100 to 1352 of SEQ ID NO:67; nucleotides 1 to 57 of SEQ ID NO:67 encode a signal peptide.

[0520] In one aspect, the mature polypeptide coding sequence is nucleotides 82 to 633 of SEQ ID NO:76; nucleotides 1 to 81 of SEQ ID NO:76 encode the signal peptide.

[0521] In one aspect, the mature polypeptide coding sequence is nucleotides 82 to 624 of SEQ ID NO:79; nucleotides 1 to 81 of SEQ ID NO:79 encode the signal peptide.

[0522] In one aspect, the mature polypeptide coding sequence is nucleotides 127 to 1023 of SEQ ID NO:82; nucleotides 1 to 126 of SEQ ID NO:82 encode the signal peptide.

[0523] In one aspect, the mature polypeptide coding sequence is nucleotides 82 to 1002 of SEQ ID NO:85; nucleotides 1 to 81 of SEQ ID NO:85 encode the signal peptide.

[0524] In one aspect, the mature polypeptide coding sequence is the combination of nucleotides 58 to 269 and nucleotides 328 to 724 of SEQ ID NO:97; nucleotides 1 to 57 of SEQ ID NO:97 encode a signal peptide.

[0525] In one aspect, the mature polypeptide coding sequence is a combination of nucleotides 55 to 71, nucleotides 121 to 524, nucleotides 594 to 1054, and nucleotides 1142 to 1270 of SEQ ID NO: 100; nucleotides 1 to 54 of SEQ ID NO: 100 encode a signal peptide.

[0526] In one aspect, the mature polypeptide coding sequence is nucleotides 73 to 978 of SEQ ID NO: 103; nucleotides 1 to 72 of SEQ ID NO: 103 encode the signal peptide.

[0527] In one aspect, the mature polypeptide coding sequence is nucleotides 109 to 1500 of SEQ ID NO: 106; nucleotides 1 to 108 of SEQ ID NO: 106 encode the signal peptide.

[0528] In one aspect, the mature polypeptide coding sequence is nucleotides 82 to 1497 of SEQ ID NO: 109; nucleotides 1 to 81 of SEQ ID NO: 109 encode the signal peptide.

[0529] In one aspect, the mature polypeptide coding sequence is nucleotides 55 to 1146 of SEQ ID NO: 112; nucleotides 1 to 54 of SEQ ID NO: 112 encode the signal peptide.

[0530] In one aspect, the mature polypeptide coding sequence is nucleotides 55 to 1170 of SEQ ID NO: 115; nucleotides 1 to 54 of SEQ ID NO: 115 encode the signal peptide.

[0531] In one aspect, the mature polypeptide coding sequence is the combination of nucleotides 82 to 1135 and nucleotides 1226 to 1242 of SEQ ID NO: 118; nucleotides 1 to 81 of SEQ ID NO: 118 encode a signal peptide.

[0532] In one aspect, the mature polypeptide coding sequence is nucleotides 73 to 978 of SEQ ID NO: 121; nucleotides 1 to 72 of SEQ ID NO: 121 encode the signal peptide.

[0533] In one aspect, the mature polypeptide coding sequence is nucleotides 118 to 1476 of SEQ ID NO: 124; nucleotides 1 to 117 of SEQ ID NO: 124 encode a signal peptide.

[0534] In one aspect, the mature polypeptide coding sequence is nucleotides 82 to 1464 of SEQ ID NO: 127; nucleotides 1 to 81 of SEQ ID NO: 127 encode the signal peptide.

[0535] In one aspect, the mature polypeptide coding sequence is a combination of nucleotides 61 to 93, nucleotides 152 to 162, nucleotides 216 to 262, and nucleotides 323 to 1362 of SEQ ID NO: 130; nucleotides 1 to 60 of SEQ ID NO: 130 encode a signal peptide.

[0536] In one aspect, the mature polypeptide coding sequence is a combination of nucleotides 61 to 93, nucleotides 152 to 162, nucleotides 216 to 262, and nucleotides 323 to 1386 of SEQ ID NO: 133; nucleotides 1 to 60 of SEQ ID NO: 133 encode a signal peptide.

[0537] In one aspect, the mature polypeptide coding sequence is nucleotides 79 to 1005 of SEQ ID NO: 136; nucleotides 1 to 78 of SEQ ID NO: 136 encode the signal peptide.

[0538] In one aspect, the mature polypeptide coding sequence is the combination of nucleotides 64 to 358 and nucleotides 512 to 1128 of SEQ ID NO: 139; nucleotides 1 to 63 of SEQ ID NO: 139 encode a signal peptide.

[0539] In one aspect, the mature polypeptide coding sequence is the combination of nucleotides 64 to 358 and nucleotides 512 to 1152 of SEQ ID NO: 142; nucleotides 1 to 63 of SEQ ID NO: 142 encode a signal peptide.

[0540] In one aspect, the mature polypeptide coding sequence is nucleotides 79 to 984 of SEQ ID NO: 145; nucleotides 1 to 78 of SEQ ID NO: 145 encode the signal peptide.

[0541] In one aspect, the mature polypeptide coding sequence is nucleotides 70 to 975 of SEQ ID NO: 148; nucleotides 1 to 69 of SEQ ID NO: 148 encode the signal peptide.

[0542] In one aspect, the mature polypeptide coding sequence is nucleotides 70 to 999 of SEQ ID NO: 151; nucleotides 1 to 69 of SEQ ID NO: 151 encode the signal peptide.

[0543] In one aspect, the mature polypeptide coding sequence is nucleotides 79 to 1026 of SEQ ID NO: 154; nucleotides 1 to 78 of SEQ ID NO: 154 encode the signal peptide.

[0544] In one aspect, the mature polypeptide coding sequence is nucleotides 46 to 993 of SEQ ID NO: 157; nucleotides 1 to 45 of SEQ ID NO: 157 encode the signal peptide.

[0545] In one aspect, the mature polypeptide coding sequence is nucleotides 49 to 957 of SEQ ID NO: 160; nucleotides 1 to 48 of SEQ ID NO: 160 encode the signal peptide.

[0546] In one aspect, the mature polypeptide coding sequence is the combination of nucleotides 82 to 1147 and nucleotides 1208 to 1224 of SEQ ID NO: 163; nucleotides 1 to 81 of SEQ ID NO: 163 encode a signal peptide.

[0547] In one aspect, the mature polypeptide coding sequence is the combination of nucleotides 73 to 318, nucleotides 478 to 1333, and nucleotides 1396 to 1412 of SEQ ID NO: 166; nucleotides 1 to 72 of SEQ ID NO: 166 encode a signal peptide.

[0548] In one aspect, the mature polypeptide coding sequence is a combination of nucleotides 67 to 95, nucleotides 229 to 469, nucleotides 435 to 940, and nucleotides 1052 to 1280 of SEQ ID NO: 169; nucleotides 1 to 66 of SEQ ID NO: 169 encode a signal peptide.

[0549] In one aspect, the mature polypeptide coding sequence is the combination of nucleotides 58 to 1132 and nucleotides 1199 to 1215 of SEQ ID NO: 172; nucleotides 1 to 57 of SEQ ID NO: 172 encode a signal peptide.

[0550] In one aspect, the mature polypeptide coding sequence is the combination of nucleotides 64 to 492, nucleotides 571 to 988, and nucleotides 1080 to 1201 of SEQ ID NO: 175; nucleotides 1 to 63 of SEQ ID NO: 175 encode a signal peptide.

[0551] In one aspect, the mature polypeptide coding sequence is the combination of nucleotides 64 to 492, nucleotides 571 to 988, and nucleotides 1080 to 1225 of SEQ ID NO: 178; nucleotides 1 to 63 of SEQ ID NO: 178 encode a signal peptide.

[0552] Nucleic acid construct: The term "nucleic acid construct" means a single-stranded or double-stranded nucleic acid molecule that is isolated from a naturally occurring gene, or modified to contain a nucleic acid segment in a manner that does not exist in nature, or is synthetic, and includes one or more control sequences.

[0553] Nutrient digestibility: The term "nutrient digestibility" means the portion of a nutrient that disappears from the gastrointestinal tract or a specified section of the gastrointestinal tract (e.g., the small intestine). Nutrient digestibility can be measured as the difference between the nutrient administered to a subject and the nutrient excreted in the feces of the subject, or the difference between the nutrient administered to a subject and the nutrient retained in the digesta at a specified section of the gastrointestinal tract (e.g., the ileum).

[0554] As used herein, nutrient digestibility can be measured by collecting total excreta over a period of time and measuring the difference between the nutrients ingested and the nutrients excreted; or by using an inert marker that is not absorbed by the animal and allows the researcher to calculate the amount of nutrients that disappear in the entire gastrointestinal tract or a segment of the gastrointestinal tract. Such an inert marker can be titanium dioxide, chromium oxide, or acid-insoluble ash. Digestibility can be expressed as a percentage of the nutrient in the feed, or as a mass unit of digestible nutrients / mass unit of nutrients in the feed. As used herein, nutrient digestibility covers starch digestibility, fat digestibility, protein digestibility, and amino acid digestibility.

[0555] As used herein, energy digestibility means the total energy of the feed consumed minus the total energy of the feces, or the total energy of the feed consumed minus the total energy of the remaining digesta on a specified section of the gastrointestinal tract of the animal (e.g., the ileum). As used herein, metabolizable energy refers to apparent metabolizable energy, and means the total energy of the feed consumed minus the total energy contained in the feces, urine, and gaseous products of digestion. Energy digestibility and metabolizable energy can be measured as the difference between the total energy intake and the total energy in the digesta excreted in the feces or present in a specified section of the gastrointestinal tract, using the same methods as for measuring nutrient digestibility, with appropriate corrections for nitrogen excretion to calculate the metabolizable energy of the feed.

[0556] Operably linked: The term "operably linked" means a configuration in which a control sequence is placed at an appropriate position relative to the coding sequence of a polynucleotide such that the control sequence directs the expression of the coding sequence.

[0557] Sequence identity: The parameter "sequence identity" is used to describe the relatedness between two amino acid sequences or between two nucleotide sequences.

[0558] For the purposes of the present invention, the degree of sequence identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277) (preferably version 3.0.0 or later). Version 6.1.0 is used. The optional parameters used are a gap opening penalty of 10, a gap extension penalty of 0.5, and an EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix. The output of Needle's notation "longest identity" (obtained using the -unsimplified option) was used as the percent identity and was calculated as follows:

[0559] (number of identical residues x 100) / (length of alignment - total number of gaps in the alignment)

[0560] For purposes of the present invention, the degree of sequence identity between two deoxyribonucleotide sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) implemented in the Needle program of the EMBOSS package (EMBOSS: European Molecular Biology Open Software Suite, Rice et al., 2000, supra) (preferred 3.0.0 version or updated version). Use version 6.1.0. The optional parameters used are gap opening penalty 10, gap extension penalty 0.5, and EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix. The output of the "longest consistency" annotated by Needle (obtained using the -non-simplified option) is used as percentage consistency, and is calculated as follows:

[0561] (Number of identical DNA nucleotides x 100) / (length of alignment - total number of gaps in the alignment).

[0562] The xylose of dissolving from defatted destarch maize (DFDSM): The term "xylose of dissolving from defatted destarch maize (DFDSM)" means the total amount of xylose measured in the supernatant after incubation with the enzyme compared to the total amount of xylose present in the substrate before incubation with the enzyme. As described herein, the enzyme dissolves the xylan in the substrate into soluble fragments (polysaccharides). Since the xylose assay only measures xylose (monosaccharides), the xylan of dissolving needs to be hydrolyzed by acid to release all xylose with monosaccharides before carrying out the xylose assay. The xylose percentage of dissolving from defatted destarch maize (DFDSM) can be calculated as described in Example 23 herein, and is represented in the example by 'xylose percentage of dissolving'.

[0563] The term "solubilizing at least x% xylose from defatted destarched maize (DFDSM)" means that after incubation as described above, the total amount of xylose measured in the supernatant is at least x%. The term "solubilizing at least x-fold more xylose from DFDSM than from a GH10 or GH11 polypeptide in the absence of a GH62 polypeptide" means that after incubation as described above, the total amount of xylose measured in the supernatant using a GH10 or GH11 xylanase and a GH62 arabinofuranosidase combination is at least x-fold higher than when a GH10 or GH11 xylanase is used in the absence of a GH62 arabinofuranosidase.

[0564] Stringent conditions: Different stringent conditions are defined below.

[0565] The term "very low stringency conditions" means that for probes of at least 100 nucleotides in length, standard Southern blotting procedures are followed, with prehybridization and hybridization for 12 to 24 hours at 42° C. in 5X SSPE, 0.3% SDS, 200 micrograms / ml sheared and denatured salmon sperm DNA, and 25% formamide. The carrier material is finally washed three times at 60° C. with 2.0X SSC, 0.2% SDS for 15 minutes each time.

[0566] The term "low stringency conditions" means that for probes of at least 100 nucleotides in length, standard Southern blotting procedures are followed, with prehybridization and hybridization for 12 to 24 hours at 42° C. in 5X SSPE, 0.3% SDS, 200 micrograms / ml sheared and denatured salmon sperm DNA, and 25% formamide. The carrier material is finally washed three times at 60° C. using 1.0X SSC, 0.2% SDS for 15 minutes each time.

[0567] The term "moderate stringency conditions" means that for probes of at least 100 nucleotides in length, standard Southern blotting procedures are followed, with prehybridization and hybridization at 42° C. for 12 to 24 hours in 5X SSPE, 0.3% SDS, 200 micrograms / ml sheared and denatured salmon sperm DNA, and 35% formamide. The carrier material is finally washed three times at 65° C. using 1.0X SSC, 0.2% SDS for 15 minutes each time.

[0568] The term "moderately high stringency conditions" means that for probes of at least 100 nucleotides in length, standard Southern blotting procedures are followed, with prehybridization and hybridization for 12 to 24 hours at 42° C. in 5X SSPE, 0.3% SDS, 200 micrograms / ml sheared and denatured salmon sperm DNA, and 35% formamide. The carrier material is finally washed three times at 70° C. using 1.0X SSC, 0.2% SDS for 15 minutes each time.

[0569] The term "high stringency conditions" means that for probes of at least 100 nucleotides in length, prehybridization and hybridization are performed at 42° C. for 12 to 24 hours in 5X SSPE, 0.3% SDS, 200 micrograms / ml sheared and denatured salmon sperm DNA, and 50% formamide following standard Southern blotting procedures. The support material is finally washed three times at 70° C. for 15 minutes each using 0.5X SSC, 0.2% SDS.

[0570] The term "very high stringency conditions" means that for probes of at least 100 nucleotides in length, prehybridization and hybridization are performed at 42° C. for 12 to 24 hours in 5X SSPE, 0.3% SDS, 200 micrograms / ml sheared and denatured salmon sperm DNA, and 50% formamide following standard Southern blotting procedures. The support material is finally washed three times at 75° C. for 15 minutes each using 0.5X SSC, 0.2% SDS.

[0571] Subsequence: The term "subsequence" means a polynucleotide having one or more (eg, several) nucleotides deleted from the 5' and / or 3' end of a mature polypeptide coding sequence; wherein the subsequence encodes a fragment having arabinofuranosidase or xylanase activity.

[0572] Substantially pure polypeptide: The term "substantially pure polypeptide" means a preparation that contains up to 10%, up to 8%, up to 6%, up to 5%, up to 4%, up to 3%, up to 2%, up to 1%, and up to 0.5% by weight of other polypeptide material with which it is naturally associated or recombinantly associated. Preferably, the polypeptide is at least 92% pure, e.g., at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99% pure, at least 99.5% pure, and 100% pure, based on the weight of the total polypeptide material present in the preparation. The polypeptides of the present invention are preferably in substantially pure form. This can be achieved, for example, by preparing the polypeptide using well-known recombinant methods or using classical purification methods.

[0573] Variant: The term "variant" means a polypeptide having xylanase or arabinofuranosidase activity that comprises an alteration (i.e., a substitution, insertion, and / or deletion of one or more (several) amino acid residues) at one or more (several) positions. Substitution means replacing the amino acid occupying a position with a different amino acid; deletion means removing the amino acid occupying a position; and insertion means adding 1-3 amino acids adjacent to the amino acid occupying a position.

[0574] Xylanase: The term "xylanase" means 1,4-β-D-xylan-xylohydrolase (EC 3.2.1.8), which catalyzes the internal hydrolysis of 1,4-β-D-xylosidic bonds in xylan. Xylanase activity can be detected at 0.01% at 37°C. X-100 and 200 mM sodium phosphate (pH 6) using 0.2% AZCL-arabinoxylan as substrate. One unit of xylanase activity is defined as the production of 1.0 micromole of azurin per minute from 0.2% AZCL-arabinoxylan as substrate in 200 mM sodium phosphate (pH 6) at 37°C.

[0575] name

[0576] For purposes of the present invention, the designation [Y / F] means that the amino acid at that position can be tyrosine (Try, Y) or phenylalanine (Phe, F). Similarly, as described herein, the designation [V / G / A / I] means that the amino acid at that position can be valine (Val, V), glycine (Gly, G), alanine (Ala, A) or isoleucine (Ile, I), and so on for other combinations as described herein. Unless further limited otherwise, amino acid X is defined such that it can be any of the 20 natural amino acids. DETAILED DESCRIPTION OF THE INVENTION

[0578] The present inventors have discovered that certain arabinofuranosidases from glycoside hydrolase family 62 (referred to herein as GH62) in combination with one or more GH10 or GH11 xylanases are unexpectedly good at solubilizing the xylose backbone of sterically hindered arabinoxylans found in plant-based materials from the subfamily Panicoides. This is surprising because arabinofuranosidases known to be very good at solubilizing wheat arabinoxylans (e.g., GH43 from Humicola insolens having SEQ ID NO: 1 of WO 2006 / 114095, GH51 from Glechoma gigantea having SEQ ID NO: 2 of WO 2006 / 114095, or a combination of both) are unable to solubilize highly substituted arabinoxylans found in, for example, maize, corn, sorghum, switchgrass, foxtail millet, pearl millet, and foxtail millet.

[0579] The amount of starch present in untreated plant material makes it difficult to detect the significant dissolution of arabinoxylan. Therefore, the starch and fat present in the plant material are removed without affecting the substitution degree pattern substrate can be used to help measure the improved enzyme combination that is better than known prior art combination. A pattern substrate is defatted destarch maize (DFDSM), and can be prepared as described in the experimental part of this paper. Importantly, this pattern substrate is not prepared using strongly acidic or alkaline conditions or high temperature, because such conditions can remove the side chain carbohydrate molecules and / or ester groups present on the xylan backbone. If these side chain groups are removed, then complexity and substitution degree will be reduced, and a kind of arabinoxylan material that is easily degraded by known solutions is obtained. It is for this reason that heat, acid and / or alkali pretreatment are used in biomass conversion.

[0580] The dissolution of arabinoxylan can be measured as the amount of xylose released into the supernatant. The increased dissolved amount will cause more xylose to be released, which can be detected using, for example, the xylose assay method as described herein. Without wishing to be bound by theory, it is believed that increasing the dissolution of arabinoxylan opens the cell wall, which can cause trapped nutrition such as starch to be released. The release of starch and other nutrients can cause improved animal performance and / or biomass to, for example, improved conversion of ethanol.

[0581] Arabinofuranosidases with this surprising property all include the motif [H / Y][L / M]F[F / S][A / C / H / S / T / V][A / D / G / N / R]D[D / E / N]G (SEQ ID NO: 1). As far as the inventors know so far, this motif is only found in arabinofuranosidases from family GH62 and is present in the polypeptides of the present invention.

[0582] Thus, in a first aspect, the invention relates to a composition comprising one or more GH10 or GH11 polypeptides having xylanase activity and one or more GH62 polypeptides having arabinofuranosidase activity, wherein:

[0583] (a) GH62 polypeptide comprises the motif [H / Y][L / M]F[F / S][A / C / H / S / T / V][A / D / G / N / R]D[D / E / N]G (SEQ ID NO: 1);

[0584] (b) the GH10 or GH11 polypeptide together with the GH62 polypeptide solubilizes at least 2.0% xylose from defatted destarched maize (DFDSM); and

[0585] (c) the GH10 or GH11 polypeptide together with the GH62 polypeptide solubilizes at least 2 times more xylose from DFDSM than the GH10 or GH11 polypeptide can solubilize in the absence of the GH62 polypeptide;

[0586] Wherein (b) and (c) are carried out under the following reaction conditions:

[0587] i) 25 mg GH10 or GH11 polypeptide / kg DFDSM,

[0588] ii) 12.5 mg GH62 polypeptide / kg DFDSM, and

[0589] iii) Incubate at 40°C, pH 5 for 4 hours.

[0590] In an alternative first aspect, the invention relates to a composition comprising one or more GH10 or GH11 polypeptides having xylanase activity and one or more GH62 polypeptides having arabinofuranosidase activity, wherein:

[0591] (a) GH62 polypeptide comprises the motif [H / Y][L / M]F[F / S][A / C / H / S / T / V][A / D / G / N / R]D[D / E / N]G (SEQ ID NO: 1);

[0592] (b) the GH10 or GH11 polypeptide together with the GH62 polypeptide solubilizes at least 2.0% xylose from defatted destarched maize (DFDSM); and

[0593] (c) the GH10 or GH11 polypeptide together with the GH62 polypeptide solubilizes at least 2 times more xylose from DFDSM than the GH10 or GH11 polypeptide can solubilize in the absence of the GH62 polypeptide;

[0594] Wherein (b) and (c) are carried out under the following reaction conditions:

[0595] i) 10 mg GH10 or GH11 polypeptide / kg DFDSM,

[0596] ii) 10 mg GH62 polypeptide / kg DFDSM, and

[0597] iii) Incubate at 40°C, pH 5 for 4 hours.

[0598] In one embodiment, the amino acid in the position 1 of the motif is histidine or tyrosine. In one embodiment, the amino acid in the position 2 of the motif is leucine. In one embodiment, the amino acid in the position 4 of the motif is phenylalanine or serine. In one embodiment, the amino acid in the position 5 of the motif is alanine, serine or valine. In one embodiment, the amino acid in the position 6 of the motif is alanine, aspartic acid or glycine. In one embodiment, the amino acid in the position 8 of the motif is asparagine. In a preferred embodiment, the GH62 polypeptide includes the motif [H / Y] LF[F / S][A / S / V][A / D / G]DNG (SEQ ID NO:2).

[0599] In one embodiment, the amino acid in position 1 of the motif is tyrosine. In one embodiment, the amino acid in position 2 of the motif is leucine. In one embodiment, the amino acid in position 4 of the motif is phenylalanine. In one embodiment, the amino acid in position 5 of the motif is alanine, cysteine ​​or valine, preferably alanine or valine, more preferably alanine. In one embodiment, the amino acid in position 6 of the motif is alanine, aspartic acid or glycine, preferably alanine or glycine, more preferably glycine. In one embodiment, the amino acid in position 8 of the motif is asparagine. In a preferred embodiment, the GH62 polypeptide includes the motif YLFF[A / V][A / G]DNG (SEQ ID NO:3), even more preferably the motif YLFFAGDNG (SEQ ID NO:4).

[0600] In one embodiment, the amino acid in position 1 of the motif is histidine or tyrosine, preferably tyrosine. In one embodiment, the amino acid in position 2 of the motif is leucine. In one embodiment, the amino acid in position 4 of the motif is serine. In one embodiment, the amino acid in position 5 of the motif is serine or threonine, preferably serine. In one embodiment, the amino acid in position 6 of the motif is aspartic acid or glycine, preferably aspartic acid. In one embodiment, the amino acid in position 8 of the motif is asparagine. In a preferred embodiment, the GH62 polypeptide comprises the motif [H / Y] LFSSDDNG (SEQ ID NO: 5), even more preferably comprising the motif YLFSSDDNG (SEQ ID NO: 6).

[0601] In an alternative first aspect, the invention relates to an animal feed or an animal feed additive comprising one or more GH10 or GH11 polypeptides having xylanase activity and one or more GH62 polypeptides having arabinofuranosidase activity, wherein:

[0602] (a) GH62 polypeptide comprises the motif [H / Y][L / M]F[F / S][A / C / H / S / T / V][A / D / G / N / R]D[D / E / N]G (SEQ ID NO: 1);

[0603] (b) the GH10 or GH11 polypeptide together with the GH62 polypeptide solubilizes at least 2.0% xylose from defatted and destarched maize (DFDSM);

[0604] (c) the GH10 or GH11 polypeptide together with the GH62 polypeptide solubilizes at least 2 times more xylose from DFDSM than the GH10 or GH11 polypeptide can solubilize in the absence of the GH62 polypeptide;

[0605] Wherein (b) and (c) are carried out under the following reaction conditions:

[0606] i) 10 mg GH10 or GH11 polypeptide / kg DFDSM,

[0607] ii) 10 mg GH62 polypeptide / kg DFDSM, and

[0608] iii) incubating at 40° C., pH 5 for 4 hours;

[0609] (d) GH10 or GH11 polypeptide is administered at 0.01-200 mg enzyme protein per kg animal feed; and

[0610] (e) GH62 polypeptide is administered at 0.01-200 mg enzyme protein per kg animal feed.

[0611] The following data points were obtained, which demonstrate the versatility of the present invention.

[0612]

[0613]

[0614]

[0615] Composition of GH62 polypeptide

[0616] Preferred embodiments of the first aspect of the present invention are disclosed below, relating to GH62 polypeptides having arabinofuranosidase activity.

[0617] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO:8.

[0618] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO:8. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO:8 or its allelic variant; comprises the amino acid sequence of SEQ ID NO:8 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO:8. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO:8. In one embodiment, the polypeptide has been isolated.

[0619] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO:9. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO:9. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO:9. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO:9. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO:9. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO:9. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO:9. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO:9. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO:9. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO:9. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO:9. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 9. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 9. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 9. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 9. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 9.

[0620] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO:9. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO:9 or its allelic variant; comprises SEQ ID NO:9 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO:9. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO:9. In one embodiment, the polypeptide has been isolated.

[0621] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 11.

[0622] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of the mature polypeptide of SEQ ID NO: 11. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 11 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 11 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 11. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 303 of SEQ ID NO: 11. In one embodiment, the polypeptide has been isolated.

[0623] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 12. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 12. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 12. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 12. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 12. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 12. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 12. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 12. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 12. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 12. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 12. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 12. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 12. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 12. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 12. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 12.

[0624] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 12. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 12 or an allelic variant thereof; comprises SEQ ID NO: 12 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 12. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 303 of SEQ ID NO: 12. In one embodiment, the polypeptide has been isolated.

[0625] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 14.

[0626] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of the mature polypeptide of SEQ ID NO: 14. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 14 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 14 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 14. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 382 of SEQ ID NO: 14. In one embodiment, the polypeptide has been isolated.

[0627] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 15. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 15. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 15. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 15. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 15. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 15. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 15. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 15. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 15. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 15. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 15. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 15. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 15. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 15. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 15. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 15.

[0628] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 15. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 15 or its allelic variant; comprises SEQ ID NO: 15 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 15. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 382 of SEQ ID NO: 15. In one embodiment, the polypeptide has been isolated.

[0629] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 17.

[0630] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of the mature polypeptide of SEQ ID NO: 17. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 17 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 17 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 17. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 378 of SEQ ID NO: 17. In one embodiment, the polypeptide has been isolated.

[0631] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 18. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 18. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 18. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 18. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 18. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 18. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 18. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 18. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 18. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 18. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 18. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 18. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 18. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 18. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 18. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 18.

[0632] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 18. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 18 or its allelic variant; comprises SEQ ID NO: 18 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 18. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 378 of SEQ ID NO: 18. In one embodiment, the polypeptide has been isolated.

[0633] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 20.

[0634] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 20. In one embodiment, the polypeptide preferably comprises the amino acid sequence of SEQ ID NO: 20 or its allelic variant, or consists thereof; comprises the amino acid sequence of SEQ ID NO: 20 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 20. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 311 of SEQ ID NO: 20. In one embodiment, the polypeptide has been isolated.

[0635] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 21. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 21. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 21. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 21. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 21. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 21. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 21. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 21. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 21. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 21. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 21. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 21. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 21. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 21. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 21. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 21.

[0636] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 21. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 21 or its allelic variant; comprises SEQ ID NO: 21 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 21. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 311 of SEQ ID NO: 21. In one embodiment, the polypeptide has been isolated.

[0637] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO:23.

[0638] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of the mature polypeptide of SEQ ID NO: 23. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 23 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 23 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 23. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO: 23. In one embodiment, the polypeptide has been isolated.

[0639] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 24. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 24. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 24. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 24. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 24. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 24. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 24. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 24. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 24. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 24. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 24. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 24. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 24. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 24. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 24. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 24.

[0640] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 24. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 24 or its allelic variant; comprises SEQ ID NO: 24 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 24. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO: 24. In one embodiment, the polypeptide has been isolated.

[0641] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO:26.

[0642] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of the mature polypeptide of SEQ ID NO: 26. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 26 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 26 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 26. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 309 of SEQ ID NO: 26. In one embodiment, the polypeptide has been isolated.

[0643] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 27. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 27. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 27. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 27. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 27. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 27. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 27. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 27. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 27. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 27. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 27. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 27. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 27. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 27. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 27. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 27.

[0644] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 27. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 27 or its allelic variant; comprises SEQ ID NO: 27 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 27. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 309 of SEQ ID NO: 27. In one embodiment, the polypeptide has been isolated.

[0645] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 29.

[0646] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 29. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 29 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 29 and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as the mature polypeptide of SEQ ID NO: 32 or SEQ ID NO: 33; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 29. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 438 of SEQ ID NO: 29. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 32. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 446 of SEQ ID NO: 32. In one embodiment, the polypeptide has been isolated.

[0647] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO:30. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO:30. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO:30. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO:30. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO:30. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO:30. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO:30. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO:30. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO:30. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO:30. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 30. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 30. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 30. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 30. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 30. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 30.

[0648] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 30. In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 33. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 30 or its allelic variant; comprises SEQ ID NO: 30 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as SEQ ID NO: 33; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 30. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 438 of SEQ ID NO: 30. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 446 of SEQ ID NO: 33. In one embodiment, the polypeptide has been isolated.

[0649] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO:35.

[0650] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of the mature polypeptide of SEQ ID NO:35. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO:35 or its allelic variant; comprises the amino acid sequence of SEQ ID NO:35 and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as the mature polypeptide of SEQ ID NO:38 or SEQ ID NO:39; or is a fragment thereof, the fragment having arabinofuranosidase activity and having at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO:35. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 438 of SEQ ID NO:35. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO:38. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 446 of SEQ ID NO: 38. In one embodiment, the polypeptide has been isolated.

[0651] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO:36. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO:36. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO:36. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO:36. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO:36. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO:36. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO:36. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO:36. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO:36. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO:36. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 36. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 36. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 36. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 36. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 36. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 36.

[0652] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 36. In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 39. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 36 or its allelic variant; comprises SEQ ID NO: 36 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as SEQ ID NO: 39; or is a fragment thereof having arabinofuranosidase activity and having at least 90% of the length of SEQ ID NO: 36. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 438 of SEQ ID NO: 36. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 446 of SEQ ID NO: 39. In one embodiment, the polypeptide has been isolated.

[0653] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO:41.

[0654] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 41. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 41 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 41 and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as the mature polypeptide of SEQ ID NO: 44 or SEQ ID NO: 45; or is a fragment thereof, the fragment having arabinofuranosidase activity and having at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 41. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 318 of SEQ ID NO: 41. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 44. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 326 of SEQ ID NO: 44. In one embodiment, the polypeptide has been isolated.

[0655] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 42. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 42. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 42. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 42. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 42. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 42. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 42. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 42. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 42. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 42. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 42. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 42. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 42. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 42. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 42. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 42.

[0656] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 42. In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 45. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 42 or its allelic variant; comprises SEQ ID NO: 42 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as SEQ ID NO: 45; or is a fragment thereof having arabinofuranosidase activity and having at least 90% of the length of SEQ ID NO: 42. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 318 of SEQ ID NO: 42. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 326 of SEQ ID NO: 45. In one embodiment, the polypeptide has been isolated.

[0657] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO:47.

[0658] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 47. In one embodiment, the polypeptide preferably comprises the amino acid sequence of SEQ ID NO: 47 or its allelic variant, or consists thereof; comprises the amino acid sequence of SEQ ID NO: 47 and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as the mature polypeptide of SEQ ID NO: 50 or SEQ ID NO: 51; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 47. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO: 47. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 50. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 311 of SEQ ID NO: 50. In one embodiment, the polypeptide has been isolated.

[0659] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 48. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 48. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 48. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 48. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 48. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 48. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 48. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 48. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 48. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 48. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 48. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 48. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 48. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 48. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 48. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 48.

[0660] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 48. In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 51. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 48 or its allelic variant; comprises SEQ ID NO: 48 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as SEQ ID NO: 51; or is a fragment thereof having arabinofuranosidase activity and having at least 90% of the length of SEQ ID NO: 48. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO: 48. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 311 of SEQ ID NO: 51. In one embodiment, the polypeptide has been isolated.

[0661] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO:53.

[0662] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO:53. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO:53 or its allelic variant; comprises the amino acid sequence of SEQ ID NO:53 and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as the mature polypeptide of SEQ ID NO:56 or SEQ ID NO:57; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO:53. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 364 of SEQ ID NO:53. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO:56. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 373 of SEQ ID NO: 56. In one embodiment, the polypeptide has been isolated.

[0663] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO:54. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO:54. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO:54. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO:54. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO:54. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO:54. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO:54. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO:54. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO:54. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO:54. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 54. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 54. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 54. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 54. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 54. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 54.

[0664] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 54. In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 57. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 54 or its allelic variant; comprises SEQ ID NO: 54 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as SEQ ID NO: 57; or is a fragment thereof having arabinofuranosidase activity and having at least 90% of the length of SEQ ID NO: 54. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 364 of SEQ ID NO: 54. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 373 of SEQ ID NO: 57. In one embodiment, the polypeptide has been isolated.

[0665] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO:59.

[0666] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO:59. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO:65 or its allelic variant; comprises the amino acid sequence of SEQ ID NO:59 and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as the mature polypeptide of SEQ ID NO:62 or SEQ ID NO:63; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO:59. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 436 of SEQ ID NO:59. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO:62. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 444 of SEQ ID NO: 62. In one embodiment, the polypeptide has been isolated.

[0667] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO:60. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO:60. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO:60. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO:60. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO:60. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO:60. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO:60. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO:60. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO:60. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO:60. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 60. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 60. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 60. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 60. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 60. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 60.

[0668] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 60. In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 63. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 60 or its allelic variant; comprises SEQ ID NO: 60 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as SEQ ID NO: 63; or is a fragment thereof having arabinofuranosidase activity and having at least 90% of the length of SEQ ID NO: 60. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 436 of SEQ ID NO: 60. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 444 of SEQ ID NO: 63. In one embodiment, the polypeptide has been isolated.

[0669] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO:65.

[0670] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 65. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 65 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 65 and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as the mature polypeptide of SEQ ID NO: 68 or SEQ ID NO: 69; or is a fragment thereof, the fragment having arabinofuranosidase activity and having at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 65. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO: 65. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 68. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 311 of SEQ ID NO: 68. In one embodiment, the polypeptide has been isolated.

[0671] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 66. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 66. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 66. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 66. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 66. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 66. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 66. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 66. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 66. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 66. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 66. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 66. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 66. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 66. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 66. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 66.

[0672] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 66. In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 69. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 66 or an allelic variant thereof; comprises SEQ ID NO: 66 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as SEQ ID NO: 69; or is a fragment thereof having arabinofuranosidase activity and having at least 90% of the length of SEQ ID NO: 66. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO: 66. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 311 of SEQ ID NO: 69. In one embodiment, the polypeptide has been isolated.

[0673] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 104.

[0674] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 104. In one embodiment, the polypeptide preferably comprises the amino acid sequence of SEQ ID NO: 104 or its allelic variant, or consists thereof; comprises the amino acid sequence of SEQ ID NO: 104 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 104. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO: 104. In one embodiment, the polypeptide has been isolated.

[0675] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 105. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 105. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 105. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 105. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 105. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 105. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 105. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 105. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 105. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 105. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 105. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 105. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 105. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 105. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 105. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 105.

[0676] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 105. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 105 or an allelic variant thereof; comprises SEQ ID NO: 105 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 105. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO: 105. In one embodiment, the polypeptide has been isolated.

[0677] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 107.

[0678] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 107. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 107 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 107 and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as the mature polypeptide of SEQ ID NO: 110 or SEQ ID NO: 111; or is a fragment thereof, the fragment having arabinofuranosidase activity and having at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 107. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 464 of SEQ ID NO: 107. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 110. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 472 of SEQ ID NO: 110. In one embodiment, the polypeptide has been isolated.

[0679] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 108. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 108. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 108. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 108. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 108. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 108. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 108. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 108. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 108. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 108. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 108. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 108. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 108. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 108. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 108. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 108.

[0680] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 108. In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 111. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 108 or its allelic variant; comprises SEQ ID NO: 108 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as SEQ ID NO: 111; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 108. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 464 of SEQ ID NO: 108. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 472 of SEQ ID NO: 111. In one embodiment, the polypeptide has been isolated.

[0681] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 113.

[0682] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 113. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 113 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 113 and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as the mature polypeptide of SEQ ID NO: 116 or SEQ ID NO: 117; or is a fragment thereof, the fragment having arabinofuranosidase activity and having at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 113. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 364 of SEQ ID NO: 113. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 116. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 372 of SEQ ID NO: 116. In one embodiment, the polypeptide has been isolated.

[0683] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 114. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 114. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 114. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 114. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 114. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 114. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 114. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 114. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 114. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 114. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 114. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 114. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 114. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 114. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 114. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 114.

[0684] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 114. In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 117. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 114 or an allelic variant thereof; comprises SEQ ID NO: 114 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as SEQ ID NO: 117; or is a fragment thereof having arabinofuranosidase activity and having at least 90% of the length of SEQ ID NO: 114. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 364 of SEQ ID NO: 114. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 372 of SEQ ID NO: 117. In one embodiment, the polypeptide has been isolated.

[0685] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 119.

[0686] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 119. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 119 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 119 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 119. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 357 of SEQ ID NO: 119. In one embodiment, the polypeptide has been isolated.

[0687] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 120. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 120. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 120. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 120. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 120. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 120. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 120. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 120. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 120. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 120. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 120. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 120. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 120. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 120. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 120. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 120.

[0688] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 120. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 120 or an allelic variant thereof; comprises SEQ ID NO: 120 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 120. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 357 of SEQ ID NO: 120. In one embodiment, the polypeptide has been isolated.

[0689] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 122.

[0690] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of the mature polypeptide of SEQ ID NO: 122. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 122 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 122 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 122. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO: 122. In one embodiment, the polypeptide has been isolated.

[0691] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 123. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 123. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 123. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 123. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 123. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 123. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 123. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 123. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 123. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 123. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 123. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 123. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 123. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 123. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 123. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 123.

[0692] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 123. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 123 or an allelic variant thereof; comprises SEQ ID NO: 123 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 123. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO: 123. In one embodiment, the polypeptide has been isolated.

[0693] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 125.

[0694] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 125. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 125 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 125 and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as the mature polypeptide of SEQ ID NO: 128 or SEQ ID NO: 129; or is a fragment thereof, the fragment having arabinofuranosidase activity and having at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 125. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 453 of SEQ ID NO: 125. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 128. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 461 of SEQ ID NO: 128. In one embodiment, the polypeptide has been isolated.

[0695] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 126. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 126. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 126. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 126. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 126. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 126. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 126. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 126. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 126. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 126. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 126. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 126. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 126. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 126. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 126. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 126.

[0696] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 126. In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 129. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 126 or an allelic variant thereof; comprises SEQ ID NO: 126 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as SEQ ID NO: 129; or is a fragment thereof having arabinofuranosidase activity and having at least 90% of the length of SEQ ID NO: 126. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 453 of SEQ ID NO: 126. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 461 of SEQ ID NO: 129. In one embodiment, the polypeptide has been isolated.

[0697] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 131.

[0698] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 131. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 131 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 131 and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as the mature polypeptide of SEQ ID NO: 134 or SEQ ID NO: 135; or is a fragment thereof, the fragment having arabinofuranosidase activity and having at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 131. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 377 of SEQ ID NO: 131. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 134. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 385 of SEQ ID NO: 134. In one embodiment, the polypeptide has been isolated.

[0699] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 132. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 132. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 132. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 132. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 132. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 132. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 132. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 132. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 132. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 132. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 132. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 132. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 132. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 132. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 132. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 132.

[0700] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 132. In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 135. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 132 or an allelic variant thereof; comprises SEQ ID NO: 132 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as SEQ ID NO: 135; or is a fragment thereof having arabinofuranosidase activity and having at least 90% of the length of SEQ ID NO: 132. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 377 of SEQ ID NO: 132. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 385 of SEQ ID NO: 135. In one embodiment, the polypeptide has been isolated.

[0701] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 137.

[0702] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of the mature polypeptide of SEQ ID NO: 137. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 137 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 137 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 137. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 309 of SEQ ID NO: 137. In one embodiment, the polypeptide has been isolated.

[0703] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 138. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 138. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 138. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 138. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 138. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 138. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 138. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 138. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 138. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 138. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 138. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 138. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 138. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 138. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 138. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 138.

[0704] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 138. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 138 or an allelic variant thereof; comprises SEQ ID NO: 138 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 138. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 308 of SEQ ID NO: 138. In one embodiment, the polypeptide has been isolated.

[0705] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 140.

[0706] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 140. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 140 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 140 and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as the mature polypeptide of SEQ ID NO: 143 or SEQ ID NO: 144; or is a fragment thereof, the fragment having arabinofuranosidase activity and having at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 140. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 304 of SEQ ID NO: 140. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 143. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 312 of SEQ ID NO: 143. In one embodiment, the polypeptide has been isolated.

[0707] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 141. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 141. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 141. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 141. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 141. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 141. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 141. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 141. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 141. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 141. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 141. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 141. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 141. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 141. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 141. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 141.

[0708] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 141. In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 144. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 141 or its allelic variant; comprises SEQ ID NO: 141 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as SEQ ID NO: 144; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 141. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 304 of SEQ ID NO: 141. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 312 of SEQ ID NO: 144. In one embodiment, the polypeptide has been isolated.

[0709] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 146.

[0710] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of the mature polypeptide of SEQ ID NO: 146. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 146 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 146 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 146. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO: 146. In one embodiment, the polypeptide has been isolated.

[0711] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 147. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 147. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 147. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 147. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 147. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 147. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 147. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 147. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 147. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 147. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 147. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 147. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 147. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 147. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 147. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 147.

[0712] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 147. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 147 or an allelic variant thereof; comprises SEQ ID NO: 147 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 147. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO: 147. In one embodiment, the polypeptide has been isolated.

[0713] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 149.

[0714] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 149. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 149 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 149 and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as the mature polypeptide of SEQ ID NO: 152 or SEQ ID NO: 153; or is a fragment thereof, the fragment having arabinofuranosidase activity and having at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 149. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO: 149. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 152. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 310 of SEQ ID NO: 152. In one embodiment, the polypeptide has been isolated.

[0715] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 150. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 150. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 150. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 150. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 150. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 150. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 150. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 150. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 150. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 150. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 150. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 150. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 150. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 150. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 150. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 150.

[0716] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 150. In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 153. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 150 or its allelic variant; comprises SEQ ID NO: 150 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as SEQ ID NO: 153; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 150. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO: 150. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 310 of SEQ ID NO: 153. In one embodiment, the polypeptide has been isolated.

[0717] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 155.

[0718] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 155. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 155 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 155 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 155. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 316 of SEQ ID NO: 155. In one embodiment, the polypeptide has been isolated.

[0719] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 156. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 156. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 156. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 156. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 156. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 156. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 156. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 156. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 156. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 156. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 156. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 156. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 156. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 156. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 156. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 156.

[0720] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 156. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 156 or its allelic variant; comprises SEQ ID NO: 156 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 156. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 316 of SEQ ID NO: 156. In one embodiment, the polypeptide has been isolated.

[0721] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 158.

[0722] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of the mature polypeptide of SEQ ID NO: 158. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 158 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 158 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 158. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 316 of SEQ ID NO: 158. In one embodiment, the polypeptide has been isolated.

[0723] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 159. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 159. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 159. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 159. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 159. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 159. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 159. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 159. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 159. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 159. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 159. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 159. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 159. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 159. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 159. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 159.

[0724] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 159. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 159 or its allelic variant; comprises SEQ ID NO: 159 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 159. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 316 of SEQ ID NO: 159. In one embodiment, the polypeptide has been isolated.

[0725] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 161.

[0726] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 161. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 161 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 161 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 161. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 303 of SEQ ID NO: 161. In one embodiment, the polypeptide has been isolated.

[0727] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 162. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 162. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 162. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 162. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 162. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 162. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 162. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 162. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 162. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 162. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 162. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 162. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 162. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 162. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 162. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 162.

[0728] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 162. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 162 or an allelic variant thereof; comprises SEQ ID NO: 162 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 162. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 303 of SEQ ID NO: 162. In one embodiment, the polypeptide has been isolated.

[0729] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 164.

[0730] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 164. In one embodiment, the polypeptide preferably comprises the amino acid sequence of SEQ ID NO: 164 or its allelic variant, or consists thereof; comprises the amino acid sequence of SEQ ID NO: 164 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 164. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 361 of SEQ ID NO: 164. In one embodiment, the polypeptide has been isolated.

[0731] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 165. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 165. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 165. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 165. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 165. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 165. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 165. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 165. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 165. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 165. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 165. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 165. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 165. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 165. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 165. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 165.

[0732] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 165. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 165 or its allelic variant; comprises SEQ ID NO: 165 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 165. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 361 of SEQ ID NO: 165. In one embodiment, the polypeptide has been isolated.

[0733] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 167.

[0734] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 167. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 167 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 167 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 167. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 373 of SEQ ID NO: 167. In one embodiment, the polypeptide has been isolated.

[0735] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 168. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 168. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 168. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 168. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 168. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 168. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 168. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 168. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 168. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 168. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 168. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 168. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 168. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 168. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 168. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 168.

[0736] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 168. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 168 or its allelic variant; comprises SEQ ID NO: 168 or its allelic variant and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 168. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 373 of SEQ ID NO: 168. In one embodiment, the polypeptide has been isolated.

[0737] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 170.

[0738] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of the mature polypeptide of SEQ ID NO: 170. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 170 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 170 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 170. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO: 170. In one embodiment, the polypeptide has been isolated.

[0739] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 171. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 171. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 171. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 171. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 171. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 171. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 171. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 171. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 171. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 171. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 171. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 171. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 171. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 171. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 171. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 171.

[0740] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 171. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 171 or an allelic variant thereof; comprises SEQ ID NO: 171 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 171. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 302 of SEQ ID NO: 171. In one embodiment, the polypeptide has been isolated.

[0741] In another embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, wherein the GH62 polypeptide having arabinofuranosidase activity has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 173.

[0742] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of the mature polypeptide of SEQ ID NO: 173. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 173 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 173 and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, the fragment having arabinofuranosidase activity and having at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 173. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 364 of SEQ ID NO: 173. In one embodiment, the polypeptide has been isolated.

[0743] In one embodiment, the composition includes a GH62 polypeptide having arabinofuranosidase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO: 174. In one embodiment, the GH62 polypeptide has at least 85% sequence identity to SEQ ID NO: 174. In one embodiment, the GH62 polypeptide has at least 86% sequence identity to SEQ ID NO: 174. In one embodiment, the GH62 polypeptide has at least 87% sequence identity to SEQ ID NO: 174. In one embodiment, the GH62 polypeptide has at least 88% sequence identity to SEQ ID NO: 174. In one embodiment, the GH62 polypeptide has at least 89% sequence identity to SEQ ID NO: 174. In one embodiment, the GH62 polypeptide has at least 90% sequence identity to SEQ ID NO: 174. In one embodiment, the GH62 polypeptide has at least 91% sequence identity to SEQ ID NO: 174. In one embodiment, the GH62 polypeptide has at least 92% sequence identity to SEQ ID NO: 174. In one embodiment, the GH62 polypeptide has at least 93% sequence identity to SEQ ID NO: 174. In one embodiment, the GH62 polypeptide has at least 94% sequence identity to SEQ ID NO: 174. In one embodiment, the GH62 polypeptide has at least 95% sequence identity to SEQ ID NO: 174. In one embodiment, the GH62 polypeptide has at least 96% sequence identity to SEQ ID NO: 174. In one embodiment, the GH62 polypeptide has at least 97% sequence identity to SEQ ID NO: 174. In one embodiment, the GH62 polypeptide has at least 98% sequence identity to SEQ ID NO: 174. In one embodiment, the GH62 polypeptide has at least 99% sequence identity to SEQ ID NO: 174.

[0744] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 174. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 174 or an allelic variant thereof; comprises SEQ ID NO: 174 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has arabinofuranosidase activity and has at least 90% of the length of SEQ ID NO: 174. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 364 of SEQ ID NO: 174. In one embodiment, the polypeptide has been isolated.

[0745] Compositions of GH10 and GH11 polypeptides

[0746] Preferred embodiments of the first aspect of the present invention, relating to GH10 or GH11 polypeptides having xylanase activity, are disclosed below.

[0747] In one embodiment, the composition includes a GH10 polypeptide having xylanase activity, such as the xylanase (Xyl II) from Aspergillus aculeatus disclosed as SEQ ID NO: 5 in WO 1994 / 021785 and disclosed as SEQ ID NO: 70 herein.

[0748] In one embodiment, the composition includes a GH10 polypeptide having xylanase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO:70. In one embodiment, the GH10 polypeptide has at least 85% sequence identity to SEQ ID NO:70. In one embodiment, the GH10 polypeptide has at least 86% sequence identity to SEQ ID NO:70. In one embodiment, the GH10 polypeptide has at least 87% sequence identity to SEQ ID NO:70. In one embodiment, the GH10 polypeptide has at least 88% sequence identity to SEQ ID NO:70. In one embodiment, the GH10 polypeptide has at least 89% sequence identity to SEQ ID NO:70. In one embodiment, the GH10 polypeptide has at least 90% sequence identity to SEQ ID NO:70. In one embodiment, the GH10 polypeptide has at least 91% sequence identity to SEQ ID NO:70. In one embodiment, the GH10 polypeptide has at least 92% sequence identity to SEQ ID NO:70. In one embodiment, the GH10 polypeptide has at least 93% sequence identity to SEQ ID NO:70. In one embodiment, the GH10 polypeptide has at least 94% sequence identity to SEQ ID NO: 70. In one embodiment, the GH10 polypeptide has at least 95% sequence identity to SEQ ID NO: 70. In one embodiment, the GH10 polypeptide has at least 96% sequence identity to SEQ ID NO: 70. In one embodiment, the GH10 polypeptide has at least 97% sequence identity to SEQ ID NO: 70. In one embodiment, the GH10 polypeptide has at least 98% sequence identity to SEQ ID NO: 70. In one embodiment, the GH10 polypeptide has at least 99% sequence identity to SEQ ID NO: 70.

[0749] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 70. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 70 or an allelic variant thereof; comprises SEQ ID NO: 70 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof having xylanase activity and having at least 90% of the length of SEQ ID NO: 70. In another embodiment, the polypeptide comprises, or consists of, amino acids 1 to 384 of SEQ ID NO: 70. In one embodiment, the polypeptide has been isolated.

[0750] In one embodiment, the composition includes a GH10 polypeptide having xylanase activity, such as the xylanase from Fusobacterium acetobutylicum disclosed as Swissprot: Q97TP5 in J. Bacteriol. 2001, 183(16):4823 and disclosed herein as SEQ ID NO: 71.

[0751] In one embodiment, the composition includes a GH10 polypeptide having xylanase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO:71. In one embodiment, the GH10 polypeptide has at least 85% sequence identity to SEQ ID NO:71. In one embodiment, the GH10 polypeptide has at least 86% sequence identity to SEQ ID NO:71. In one embodiment, the GH10 polypeptide has at least 87% sequence identity to SEQ ID NO:71. In one embodiment, the GH10 polypeptide has at least 88% sequence identity to SEQ ID NO:71. In one embodiment, the GH10 polypeptide has at least 89% sequence identity to SEQ ID NO:71. In one embodiment, the GH10 polypeptide has at least 90% sequence identity to SEQ ID NO:71. In one embodiment, the GH10 polypeptide has at least 91% sequence identity to SEQ ID NO:71. In one embodiment, the GH10 polypeptide has at least 92% sequence identity to SEQ ID NO:71. In one embodiment, the GH10 polypeptide has at least 93% sequence identity to SEQ ID NO:71. In one embodiment, the GH10 polypeptide has at least 94% sequence identity to SEQ ID NO: 71. In one embodiment, the GH10 polypeptide has at least 95% sequence identity to SEQ ID NO: 71. In one embodiment, the GH10 polypeptide has at least 96% sequence identity to SEQ ID NO: 71. In one embodiment, the GH10 polypeptide has at least 97% sequence identity to SEQ ID NO: 71. In one embodiment, the GH10 polypeptide has at least 98% sequence identity to SEQ ID NO: 71. In one embodiment, the GH10 polypeptide has at least 99% sequence identity to SEQ ID NO: 71.

[0752] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 71. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 71 or an allelic variant thereof; comprises SEQ ID NO: 71 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has xylanase activity and has at least 90% of the length of SEQ ID NO: 71. In another embodiment, the polypeptide comprises, or consists of, amino acids 1 to 288 of SEQ ID NO: 71. In one embodiment, the polypeptide has been isolated.

[0753] In one embodiment, the composition includes a GH10 polypeptide having xylanase activity, such as the xylanase from Aspergillus aculeatus disclosed as SEQ ID NO: 8 in WO2005 / 059084 and as SEQ ID NO: 72 herein.

[0754] In one embodiment, the composition includes a GH10 polypeptide having xylanase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO:72. In one embodiment, the GH10 polypeptide has at least 85% sequence identity to SEQ ID NO:72. In one embodiment, the GH10 polypeptide has at least 86% sequence identity to SEQ ID NO:72. In one embodiment, the GH10 polypeptide has at least 87% sequence identity to SEQ ID NO:72. In one embodiment, the GH10 polypeptide has at least 88% sequence identity to SEQ ID NO:72. In one embodiment, the GH10 polypeptide has at least 89% sequence identity to SEQ ID NO:72. In one embodiment, the GH10 polypeptide has at least 90% sequence identity to SEQ ID NO:72. In one embodiment, the GH10 polypeptide has at least 91% sequence identity to SEQ ID NO:72. In one embodiment, the GH10 polypeptide has at least 92% sequence identity to SEQ ID NO:72. In one embodiment, the GH10 polypeptide has at least 93% sequence identity to SEQ ID NO:72. In one embodiment, the GH10 polypeptide has at least 94% sequence identity to SEQ ID NO: 72. In one embodiment, the GH10 polypeptide has at least 95% sequence identity to SEQ ID NO: 72. In one embodiment, the GH10 polypeptide has at least 96% sequence identity to SEQ ID NO: 72. In one embodiment, the GH10 polypeptide has at least 97% sequence identity to SEQ ID NO: 72. In one embodiment, the GH10 polypeptide has at least 98% sequence identity to SEQ ID NO: 72. In one embodiment, the GH10 polypeptide has at least 99% sequence identity to SEQ ID NO: 72.

[0755] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 72. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 72 or an allelic variant thereof; comprises SEQ ID NO: 72 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof having xylanase activity and having at least 90% of the length of SEQ ID NO: 72. In another embodiment, the polypeptide comprises, or consists of, amino acids 1 to 308 of SEQ ID NO: 72. In one embodiment, the polypeptide has been isolated.

[0756] In one embodiment, the composition includes a GH11 polypeptide having xylanase activity, such as the xylanase from Thermomyces lanuginosus disclosed as SEQ ID NO: 2 in WO 1996 / 23062 and disclosed as SEQ ID NO: 73 herein.

[0757] In one embodiment, the composition includes a GH10 polypeptide having xylanase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO:73. In one embodiment, the GH10 polypeptide has at least 85% sequence identity to SEQ ID NO:73. In one embodiment, the GH10 polypeptide has at least 86% sequence identity to SEQ ID NO:73. In one embodiment, the GH10 polypeptide has at least 87% sequence identity to SEQ ID NO:73. In one embodiment, the GH10 polypeptide has at least 88% sequence identity to SEQ ID NO:73. In one embodiment, the GH10 polypeptide has at least 89% sequence identity to SEQ ID NO:73. In one embodiment, the GH10 polypeptide has at least 90% sequence identity to SEQ ID NO:73. In one embodiment, the GH10 polypeptide has at least 91% sequence identity to SEQ ID NO:73. In one embodiment, the GH10 polypeptide has at least 92% sequence identity to SEQ ID NO:73. In one embodiment, the GH10 polypeptide has at least 93% sequence identity to SEQ ID NO:73. In one embodiment, the GH10 polypeptide has at least 94% sequence identity to SEQ ID NO: 73. In one embodiment, the GH10 polypeptide has at least 95% sequence identity to SEQ ID NO: 73. In one embodiment, the GH10 polypeptide has at least 96% sequence identity to SEQ ID NO: 73. In one embodiment, the GH10 polypeptide has at least 97% sequence identity to SEQ ID NO: 73. In one embodiment, the GH10 polypeptide has at least 98% sequence identity to SEQ ID NO: 73. In one embodiment, the GH10 polypeptide has at least 99% sequence identity to SEQ ID NO: 73.

[0758] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at positions between 1 and 10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) of SEQ ID NO: 73. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 73 or an allelic variant thereof; comprises SEQ ID NO: 73 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof having xylanase activity and having at least 90% of the length of SEQ ID NO: 73. In another embodiment, the polypeptide comprises, or consists of, amino acids 1 to 195 of SEQ ID NO: 73. In one embodiment, the polypeptide has been isolated.

[0759] In one embodiment, the composition includes a GH11 polypeptide having xylanase activity, such as the xylanase from Dictyoglobulus thermophilus disclosed as SEQ ID NO: 305 in WO2011 / 057140 and disclosed as SEQ ID NO: 74 herein.

[0760] In one embodiment, the composition includes a GH10 polypeptide having xylanase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO:74. In one embodiment, the GH10 polypeptide has at least 85% sequence identity to SEQ ID NO:74. In one embodiment, the GH10 polypeptide has at least 86% sequence identity to SEQ ID NO:74. In one embodiment, the GH10 polypeptide has at least 87% sequence identity to SEQ ID NO:74. In one embodiment, the GH10 polypeptide has at least 88% sequence identity to SEQ ID NO:74. In one embodiment, the GH10 polypeptide has at least 89% sequence identity to SEQ ID NO:74. In one embodiment, the GH10 polypeptide has at least 90% sequence identity to SEQ ID NO:74. In one embodiment, the GH10 polypeptide has at least 91% sequence identity to SEQ ID NO:74. In one embodiment, the GH10 polypeptide has at least 92% sequence identity to SEQ ID NO:74. In one embodiment, the GH10 polypeptide has at least 93% sequence identity to SEQ ID NO:74. In one embodiment, the GH10 polypeptide has at least 94% sequence identity to SEQ ID NO: 74. In one embodiment, the GH10 polypeptide has at least 95% sequence identity to SEQ ID NO: 74. In one embodiment, the GH10 polypeptide has at least 96% sequence identity to SEQ ID NO: 74. In one embodiment, the GH10 polypeptide has at least 97% sequence identity to SEQ ID NO: 74. In one embodiment, the GH10 polypeptide has at least 98% sequence identity to SEQ ID NO: 74. In one embodiment, the GH10 polypeptide has at least 99% sequence identity to SEQ ID NO: 74.

[0761] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 74. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 74 or an allelic variant thereof; comprises SEQ ID NO: 74 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has xylanase activity and has at least 90% of the length of SEQ ID NO: 74. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 203 of SEQ ID NO: 74. In one embodiment, the polypeptide has been isolated.

[0762] In one embodiment, the composition includes a GH11 polypeptide having xylanase activity, such as the xylanase from Paenibacillus pabuli disclosed as SEQ ID NO: 2 in WO2005 / 079585 and as SEQ ID NO: 75 herein.

[0763] In one embodiment, the composition includes a GH10 polypeptide having xylanase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO:75. In one embodiment, the GH10 polypeptide has at least 85% sequence identity to SEQ ID NO:75. In one embodiment, the GH10 polypeptide has at least 86% sequence identity to SEQ ID NO:75. In one embodiment, the GH10 polypeptide has at least 87% sequence identity to SEQ ID NO:75. In one embodiment, the GH10 polypeptide has at least 88% sequence identity to SEQ ID NO:75. In one embodiment, the GH10 polypeptide has at least 89% sequence identity to SEQ ID NO:75. In one embodiment, the GH10 polypeptide has at least 90% sequence identity to SEQ ID NO:75. In one embodiment, the GH10 polypeptide has at least 91% sequence identity to SEQ ID NO:75. In one embodiment, the GH10 polypeptide has at least 92% sequence identity to SEQ ID NO:75. In one embodiment, the GH10 polypeptide has at least 93% sequence identity to SEQ ID NO:75. In one embodiment, the GH10 polypeptide has at least 94% sequence identity to SEQ ID NO: 75. In one embodiment, the GH10 polypeptide has at least 95% sequence identity to SEQ ID NO: 75. In one embodiment, the GH10 polypeptide has at least 96% sequence identity to SEQ ID NO: 75. In one embodiment, the GH10 polypeptide has at least 97% sequence identity to SEQ ID NO: 75. In one embodiment, the GH10 polypeptide has at least 98% sequence identity to SEQ ID NO: 75. In one embodiment, the GH10 polypeptide has at least 99% sequence identity to SEQ ID NO: 75.

[0764] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 75. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 75 or an allelic variant thereof; comprises SEQ ID NO: 75 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag; or is a fragment thereof, which has xylanase activity and has at least 90% of the length of SEQ ID NO: 75. In another embodiment, the polypeptide comprises, or consists of, amino acids 1 to 182 of SEQ ID NO: 75. In one embodiment, the polypeptide has been isolated.

[0765] In one embodiment, the composition includes a GH11 polypeptide having xylanase activity, e.g., a xylanase from Geobacillus stearothermophilus as disclosed herein as SEQ ID NO: 78. In one embodiment, the composition includes a GH10 polypeptide having xylanase activity having at least 80%, e.g., at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the mature polypeptide of SEQ ID NO: 77.

[0766] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 77. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 77 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 77 and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as the mature polypeptide of SEQ ID NO: 80 or SEQ ID NO: 81; or is a fragment thereof, the fragment having xylanase activity and having at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 77. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 183 of SEQ ID NO: 77. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 80. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 181 of SEQ ID NO: 80. In one embodiment, the polypeptide has been isolated.

[0767] In one embodiment, the composition includes a GH10 polypeptide having xylanase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO:78. In one embodiment, the GH10 polypeptide has at least 85% sequence identity to SEQ ID NO:78. In one embodiment, the GH10 polypeptide has at least 86% sequence identity to SEQ ID NO:78. In one embodiment, the GH10 polypeptide has at least 87% sequence identity to SEQ ID NO:78. In one embodiment, the GH10 polypeptide has at least 88% sequence identity to SEQ ID NO:78. In one embodiment, the GH10 polypeptide has at least 89% sequence identity to SEQ ID NO:78. In one embodiment, the GH10 polypeptide has at least 90% sequence identity to SEQ ID NO:78. In one embodiment, the GH10 polypeptide has at least 91% sequence identity to SEQ ID NO:78. In one embodiment, the GH10 polypeptide has at least 92% sequence identity to SEQ ID NO:78. In one embodiment, the GH10 polypeptide has at least 93% sequence identity to SEQ ID NO:78. In one embodiment, the GH10 polypeptide has at least 94% sequence identity to SEQ ID NO: 78. In one embodiment, the GH10 polypeptide has at least 95% sequence identity to SEQ ID NO: 78. In one embodiment, the GH10 polypeptide has at least 96% sequence identity to SEQ ID NO: 78. In one embodiment, the GH10 polypeptide has at least 97% sequence identity to SEQ ID NO: 78. In one embodiment, the GH10 polypeptide has at least 98% sequence identity to SEQ ID NO: 78. In one embodiment, the GH10 polypeptide has at least 99% sequence identity to SEQ ID NO: 78.

[0768] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 78. In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 81. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 78 or an allelic variant thereof; comprises SEQ ID NO: 78 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as SEQ ID NO: 81; or is a fragment thereof having xylanase activity and having at least 90% of the length of SEQ ID NO: 78. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 183 of SEQ ID NO: 78. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 181 of SEQ ID NO: 81. In one embodiment, the polypeptide has been isolated.

[0769] In one embodiment, the composition includes a GH11 polypeptide having xylanase activity, such as a xylanase from Streptomyces fuscae as disclosed herein as SEQ ID NO: 84. In one embodiment, the composition includes a GH10 polypeptide having xylanase activity, which has at least 80%, such as at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% sequence identity to the mature polypeptide of SEQ ID NO: 83.

[0770] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of the mature polypeptide of SEQ ID NO: 83. In one embodiment, the polypeptide preferably comprises or consists of the amino acid sequence of SEQ ID NO: 83 or its allelic variant; comprises the amino acid sequence of SEQ ID NO: 83 and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as the mature polypeptide of SEQ ID NO: 86 or SEQ ID NO: 87; or is a fragment thereof, which has xylanase activity and has at least 90% of the length of the mature polypeptide. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 83. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 299 of SEQ ID NO: 83. In another embodiment, the polypeptide comprises or consists of the mature polypeptide of SEQ ID NO: 86. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 307 of SEQ ID NO: 86. In one embodiment, the polypeptide has been isolated.

[0771] In one embodiment, the composition includes a GH10 polypeptide having xylanase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO:84. In one embodiment, the GH10 polypeptide has at least 85% sequence identity to SEQ ID NO:84. In one embodiment, the GH10 polypeptide has at least 86% sequence identity to SEQ ID NO:84. In one embodiment, the GH10 polypeptide has at least 87% sequence identity to SEQ ID NO:84. In one embodiment, the GH10 polypeptide has at least 88% sequence identity to SEQ ID NO:84. In one embodiment, the GH10 polypeptide has at least 89% sequence identity to SEQ ID NO:84. In one embodiment, the GH10 polypeptide has at least 90% sequence identity to SEQ ID NO:84. In one embodiment, the GH10 polypeptide has at least 91% sequence identity to SEQ ID NO:84. In one embodiment, the GH10 polypeptide has at least 92% sequence identity to SEQ ID NO:84. In one embodiment, the GH10 polypeptide has at least 93% sequence identity to SEQ ID NO:84. In one embodiment, the GH10 polypeptide has at least 94% sequence identity to SEQ ID NO: 84. In one embodiment, the GH10 polypeptide has at least 95% sequence identity to SEQ ID NO: 84. In one embodiment, the GH10 polypeptide has at least 96% sequence identity to SEQ ID NO: 84. In one embodiment, the GH10 polypeptide has at least 97% sequence identity to SEQ ID NO: 84. In one embodiment, the GH10 polypeptide has at least 98% sequence identity to SEQ ID NO: 84. In one embodiment, the GH10 polypeptide has at least 99% sequence identity to SEQ ID NO: 84.

[0772] In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 84. In one embodiment, the polypeptide comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at between 1 and 10 positions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions) of SEQ ID NO: 87. In one embodiment, the polypeptide preferably comprises, or consists of, the amino acid sequence of SEQ ID NO: 84 or an allelic variant thereof; comprises SEQ ID NO: 84 or an allelic variant thereof and an N-terminal and / or C-terminal His-tag and / or HQ-tag, such as SEQ ID NO: 87; or is a fragment thereof having xylanase activity and having at least 90% of the length of SEQ ID NO: 84. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 299 of SEQ ID NO: 84. In another embodiment, the polypeptide comprises or consists of amino acids 1 to 307 of SEQ ID NO: 87. In one embodiment, the polypeptide has been isolated.

[0773] In one embodiment, the composition includes a GH11 polypeptide having xylanase activity, such as the xylanase from Fusarium oxysporum known as FoxXyn6 disclosed as SEQ ID NO: 2 in WO2014 / 019220 and as SEQ ID NO: 88 herein.

[0774] In one embodiment, the composition includes a GH10 polypeptide having xylanase activity, the polypeptide having at least 80% sequence identity to SEQ ID NO:88. In one embodiment, the GH10 polypeptide has at least 85% sequence identity to SEQ ID NO:88. In one embodiment, the GH10 polypeptide has at least 86% sequence identity to SEQ ID NO:88. In one embodiment, the GH10 polypeptide has at least 87% sequence identity to SEQ ID NO:88. In one embodiment, the GH10 polypeptide has at least 88% sequence identity to SEQ ID NO:88. In one embodiment, the GH10 polypeptide has at least 89% sequence identity to SEQ ID NO:88. In one embodiment, the GH10 polypeptide has at least 90% sequence identity to SEQ ID NO:88. In one embodiment, the GH10 polypeptide has at least 91% sequence identity to SEQ ID NO:88. In one embodiment, the GH10 polypeptide has at least 92% sequence identity to SEQ ID NO:88. In one embodiment, the GH10 polypeptide has at least 93% sequence identity to SEQ ID NO:88. In one embodiment, the GH10 polypeptide ha...

Claims

1. An isolated polypeptide having arabinofuranosidase activity, the polypeptide being selected from the group consisting of: (a) a polypeptide having at least 85% sequence identity to the polypeptide of SEQ ID NO: 12; (b) a polypeptide having at least 97.6% sequence identity to the polypeptide of SEQ ID NO: 24; (c) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 27; (d) a polypeptide having at least 90% sequence identity to the polypeptide of SEQ ID NO: 30; (e) a polypeptide having at least 92% sequence identity to the polypeptide of SEQ ID NO: 36; (f) a polypeptide having at least 86% sequence identity to the polypeptide of SEQ ID NO:48; (g) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO:54; (h) a polypeptide having at least 81% sequence identity to the polypeptide of SEQ ID NO: 60; (i) a polypeptide having at least 84% sequence identity to the polypeptide of SEQ ID NO: 66; (j) a polypeptide having at least 87% sequence identity to the polypeptide of SEQ ID NO: 105; (k) a polypeptide having at least 85% sequence identity to the polypeptide of SEQ ID NO: 108; (l) a polypeptide having at least 80% sequence identity with the polypeptide of SEQ ID NO: 114; (m) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 120; (n) a polypeptide having at least 89% sequence identity to the polypeptide of SEQ ID NO: 123; (o) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 126; (p) a polypeptide having at least 85% sequence identity to the polypeptide of SEQ ID NO: 138; (q) a polypeptide having at least 89% sequence identity to the polypeptide of SEQ ID NO: 141; (r) a polypeptide having at least 86% sequence identity to the polypeptide of SEQ ID NO: 147; (s) a polypeptide having at least 96.4% sequence identity to the polypeptide of SEQ ID NO: 156; (t) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 162; (u) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 165; (v) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 168; (w) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 171; (x) a polypeptide having at least 82% sequence identity to the polypeptide of SEQ ID NO: 174; (y) a polypeptide encoded by a polynucleotide that hybridizes under high stringency conditions or very high stringency conditions to (i) the mature polypeptide coding sequence of SEQ ID NO: 10, (ii) the mature polypeptide coding sequence of SEQ ID NO: 22, (iii) the mature polypeptide coding sequence of SEQ ID NO: 25, (iv) the mature polypeptide coding sequence of SEQ ID NO: 28, (v) the mature polypeptide coding sequence of SEQ ID NO:34, (vi) the mature polypeptide coding sequence of SEQ ID NO:46, (vii) the mature polypeptide coding sequence of SEQ ID NO:52, (viii) the mature polypeptide coding sequence of SEQ ID NO:58, (ix) the mature polypeptide coding sequence of SEQ ID NO: 64, (x) the mature polypeptide coding sequence of SEQ ID NO: 103, (xi) the mature polypeptide coding sequence of SEQ ID NO: 106, (xii) the mature polypeptide coding sequence of SEQ ID NO: 112, (xiii) the mature polypeptide coding sequence of SEQ ID NO: 118, (xiv) the mature polypeptide coding sequence of SEQ ID NO: 121, (xv) the mature polypeptide coding sequence of SEQ ID NO: 124, (xvi) the mature polypeptide coding sequence of SEQ ID NO: 136, (xvii) the mature polypeptide coding sequence of SEQ ID NO: 139, (xviii) the mature polypeptide coding sequence of SEQ ID NO: 145, (xix) the mature polypeptide coding sequence of SEQ ID NO: 154, (xx) the mature polypeptide coding sequence of SEQ ID NO: 160, (xxi) the mature polypeptide coding sequence of SEQ ID NO: 163, (xxii) the mature polypeptide coding sequence of SEQ ID NO: 166, (xxiii) the mature polypeptide coding sequence of SEQ ID NO: 169, (xxiv) the mature polypeptide coding sequence of SEQ ID NO: 172, (xxv) the full complementary strand of (i), (ii), (iii), (iv), (v), (vi), (vii), (viii), (ix), (x), (xi), (xii), (xiii), (xiv), (xv), (xvi), (xvii), (xviii), (xix), (xx), (xxi), (xxii), (xxiii), or (xxiv); (z) a polypeptide encoded by a polynucleotide having at least 85% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 10; (aa) a polypeptide encoded by the following polynucleotide, which has at least 97.6% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 22; (ab) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 25; (ac) a polypeptide encoded by a polynucleotide having at least 90% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 28; (ad) a polypeptide encoded by the following polynucleotide, which has at least 92% sequence identity with the mature polypeptide coding sequence of SEQ ID NO:34; (ae) a polypeptide encoded by a polynucleotide having at least 86% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 46; (af) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:52; (ag) a polypeptide encoded by a polynucleotide having at least 81% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 58; (ah) a polypeptide encoded by the following polynucleotide, which has at least 84% sequence identity to the mature polypeptide coding sequence of SEQ ID NO:64; (ai) a polypeptide encoded by a polynucleotide having at least 87% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 103; (aj) a polypeptide encoded by a polynucleotide having at least 85% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 106; (ak) a polypeptide encoded by the following polynucleotide, which has at least 80% sequence identity with the mature polypeptide coding sequence of SEQ ID NO: 111; (a1) a polypeptide encoded by the following polynucleotide, which has at least 80% sequence identity with the mature polypeptide coding sequence of SEQ ID NO: 118; (am) a polypeptide encoded by the following polynucleotide, which has at least 89% sequence identity with the mature polypeptide coding sequence of SEQ ID NO: 121; (an) a polypeptide encoded by the following polynucleotide, which has at least 80% sequence identity with the mature polypeptide coding sequence of SEQ ID NO: 124; (ao) a polypeptide encoded by the following polynucleotide, which has at least 85% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 136; (ap) a polypeptide encoded by a polynucleotide having at least 89% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 139; (aq) a polypeptide encoded by the following polynucleotide, which has at least 86% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 145; (ar) a polypeptide encoded by the following polynucleotide, which has at least 96.4% sequence identity with the mature polypeptide coding sequence of SEQ ID NO: 154; (as) a polypeptide encoded by the following polynucleotide, which has at least 80% sequence identity with the mature polypeptide coding sequence of SEQ ID NO: 160; (at) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 163; (au) a polypeptide encoded by the following polynucleotide, which has at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 166; (av) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 169; (aw) a polypeptide encoded by a polynucleotide having at least 82% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 172; (ax) a variant of SEQ ID NO: 12, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44 or 45 position; (ay) a variant of SEQ ID NO: 24, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions in 1, 2, 3, 4, 5, 6 or 7 positions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof; (az) a variant of a polypeptide selected from the group consisting of SEQ ID NO: 27, SEQ ID NO: 54, SEQ ID NO: 60, SEQ ID NO: 108, SEQ ID NO: 114, SEQ ID NO: 120, SEQ ID NO: 126, SEQ ID NO: 162, SEQ ID NO: 165, SEQ ID NO: 168, SEQ ID NO: 171 or SEQ ID NO:

172. NO: 174, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 positions; (ba) a variant of SEQ ID NO:30, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42 or 43 positions; (bb) a variant of SEQ ID NO:36, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33 or 34 positions; (bc) a variant of a polypeptide selected from the group consisting of SEQ ID NO:48 or SEQ ID NO:147, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 or 42 positions; (bd) a variant of SEQ ID NO:66, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 or 48 positions; (be) a variant of SEQ ID NO: 105, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38 or 39 positions; (bf) a variant of a polypeptide selected from the group consisting of SEQ ID NO: 123 or SEQ ID NO: 141, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32 or 33 positions; (bg) a variant of SEQ ID NO: 138, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45 or 46 positions; (bh) a variant of SEQ ID NO: 156, wherein the variant has arabinofuranosidase activity and comprises one or more amino acid substitutions in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 positions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof; (bi) a polypeptide comprising the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q), (r), (s), (t), (u), (v), (w), (x), (y), (z), (aa), (ab), (ac), (ad), (ae), (af), (ag), (ah), (ai), (aj), (ak), (al), (am), (an), (ao), (ap), (aq), (ar), (as), (at), (au), (av), (aw), (ax), (ay), (az), (ba), (bb), (bc), (bd), (be), (bf), (bg) or (bh) and an N-terminal and / or C-terminal His-tag and / or HQ-tag; [0013] The invention further comprises a fragment of a polypeptide of the type A, B, C, D, E, F, G, H, I, J, K, L, M, N, O, P, Q, R, S, T, U, V, W, X, Y, Z, Aa, Ab, Aca ...

2. The polypeptide according to claim 1, wherein the polypeptide comprises or consists of: amino acids 1 to 303 of SEQ ID NO:12, amino acids 1 to 302 of SEQ ID NO:24, amino acids 1 to 309 of SEQ ID NO:27, amino acids 1 to 438 of SEQ ID NO:30, amino acids 1 to 446 of SEQ ID NO:33, amino acids 1 to 438 of SEQ ID NO:36, amino acids 1 to 446 of SEQ ID NO:39, amino acids 1 to 302 of SEQ ID NO:48, amino acids 1 to 311 of SEQ ID NO:51, amino acids 1 to 364 of SEQ ID NO:54, amino acids 1 to 373 of SEQ ID NO:57, amino acids 1 to 436 of SEQ ID NO:60, amino acids 1 to 444 of SEQ ID NO:63, amino acids 1 to 302 of SEQ ID NO:66, amino acids 1 to 311 of SEQ ID NO:105, amino acids 1 to 464 of SEQ ID NO:108, 1 to 472 of SEQ ID NO: 111, amino acids 1 to 364 of SEQ ID NO: 114, amino acids 1 to 372 of SEQ ID NO: 117, amino acids 1 to 357 of SEQ ID NO: 120, amino acids 1 to 302 of SEQ ID NO: 123, amino acids 1 to 453 of SEQ ID NO: 126, amino acids 1 to 461 of SEQ ID NO: 129, amino acids 1 to 309 of SEQ ID NO: 138, amino acids 1 to 304 of SEQ ID NO: 141, amino acids 1 to 312 of SEQ ID NO: 144, amino acids 1 to 302 of SEQ ID NO: 147, amino acids 1 to 316 of SEQ ID NO: 156, amino acids 1 to 303 of SEQ ID NO: 162, amino acids 1 to 361 of SEQ ID NO: 165, amino acids 1 to 373 of SEQ ID NO: 168, amino acids 1 to 302 of SEQ ID NO: 171, or amino acids 1 to 304 of SEQ ID NO: 141, amino acids 1 to 312 of SEQ ID NO: 144, amino acids 1 to 302 of SEQ ID NO:

147. Amino acids 1 to 364 of NO:

174.

3. A composition comprising one or more polypeptides according to any one of claims 1 to 2.

4. The composition of claim 3, further comprising one or more GH10 or GH11 polypeptides having xylanase activity.

5. The composition of claim 4, wherein the GH10 or GH11 polypeptide having xylanase activity is selected from the group consisting of: (a) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 70; (b) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 71; (c) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 72; (d) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 73; (e) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 74; (f) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 75; (g) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 78; (h) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 81; (i) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 84; (j) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 88; (k) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 89; (l) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO:95; (m) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO:96; (n) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO:99; (o) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 102; (p) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 177; (q) a variant of a polypeptide selected from the group consisting of SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:78, SEQ ID NO:81, SEQ ID NO:84, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:99, SEQ ID NO:102, and SEQ ID NO:177, wherein the variant has xylanase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions in 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 positions, or any combination thereof; (r) a polypeptide comprising the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p) or (q) and an N-terminal and / or C-terminal His-tag and / or HQ-tag; and (s) (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), (l), (m), (n), (o), (p), (q) or (r) The fragment has xylanase activity and has at least 90% of the length of the mature polypeptide.

6. The composition according to claim 5, wherein the GH10 or GH11 polypeptide having xylanase activity is selected from the group consisting of: amino acids 1 to 384 of SEQ ID NO:70, amino acids 1 to 288 of SEQ ID NO:71, amino acids 1 to 308 of SEQ ID NO:72, amino acids 1 to 195 of SEQ ID NO:73, amino acids 1 to 203 of SEQ ID NO:74, amino acids 1 to 182 of SEQ ID NO:75, amino acids 1 to 183 of SEQ ID NO:78, amino acids 1 to 181 of SEQ ID NO:81, amino acids 1 to 299 of SEQ ID NO:84, amino acids 1 to 307 of SEQ ID NO:87, amino acids 1 to 188 of SEQ ID NO:88, amino acids 1 to 189 of SEQ ID NO:89, amino acids 1 to 328 of SEQ ID NO:95, amino acids 1 to 208 of SEQ ID NO:96, amino acids 1 to 203 of SEQ ID NO:99, amino acids 1 to 337 of SEQ ID NO:102, or amino acids 1 to 323 of SEQ ID NO:

177.

7. An isolated polypeptide having xylanase activity, the isolated polypeptide being selected from the group consisting of: (a) a polypeptide having at least 84% sequence identity to the polypeptide of SEQ ID NO: 84; (b) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 99; (c) a polypeptide having at least 80% sequence identity to the polypeptide of SEQ ID NO: 102; (d) a polypeptide encoded by a polynucleotide that hybridizes under high stringency conditions or very high stringency conditions to (i) the mature polypeptide coding sequence of SEQ ID NO: 82, (ii) the mature polypeptide coding sequence of SEQ ID NO:97, (iii) the mature polypeptide coding sequence of SEQ ID NO: 100, (iv) the full-length complementary strand of (i), (ii) or (iii); (e) a polypeptide encoded by a polynucleotide having at least 84% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 82; (f) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 97; (g) a polypeptide encoded by a polynucleotide having at least 80% sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 100; (h) a variant of a polypeptide selected from the group consisting of SEQ ID NO:84, SEQ ID NO:99 or SEQ ID NO:102, wherein the variant has xylanase activity and comprises one or more amino acid substitutions, and / or one or more amino acid deletions, and / or one or more amino acid insertions, or any combination thereof, in 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 positions; (i) a polypeptide comprising the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h) or (i) and an N-terminal and / or C-terminal His-tag and / or HQ-tag; and (j) a fragment of the polypeptide of (a), (b), (c), (d), (e), (f), (g), (h), (i) or (j), which fragment has xylanase activity and has at least 90% of the length of the mature polypeptide.

8. The polypeptide according to claim 7, wherein the polypeptide comprises or consists of: Amino acids 1 to 299 of SEQ ID NO:84, amino acids 1 to 307 of SEQ ID NO:87, amino acids 1 to 203 of SEQ ID NO:99, or amino acids 1 to 337 of SEQ ID NO:

102.

9. A polynucleotide encoding the polypeptide of any one of claims 1 to 2 or 7 to 8.

10. A nucleic acid construct or expression vector comprising the polynucleotide of claim 9 operably linked to one or more control sequences that direct the production of the polypeptide in an expression host.

11. A recombinant host cell comprising the polynucleotide of claim 9 operably linked to one or more control sequences that direct the production of the polypeptide.

12. A method for producing the polypeptide of any one of claims 1 to 2 or 7 to 8, the method comprising: (a) culturing the recombinant host cell of claim 11 under conditions conducive to production of the polypeptide; and (b) recovering the polypeptide.

Images